Ask OpenScientist

Ask a research question about Omodysplasia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

2
Inheritance
3
Pathophys.
22
Phenotypes
5
Pathograph
2
Genes
3
Treatments
2
Subtypes
2
Deep Research
👪

Inheritance

2
Autosomal recessive HP:0000007
Autosomal recessive omodysplasia is caused by biallelic mutations in GPC6, including point mutations and larger genomic rearrangements. Parental consanguinity is common among reported families.
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:19481194 SUPPORT Human Clinical
"autosomal-recessive omodysplasia, a genetic condition characterized by short-limbed short stature, craniofacial dysmorphism, and variable developmental delay, maps to chromosome 13 (13q31.1-q32.2) and is caused by point mutations or by larger genomic rearrangements in glypican 6 (GPC6)"
Identifies GPC6 as the causative gene for autosomal recessive omodysplasia via linkage mapping and mutation analysis.
Autosomal dominant HP:0000006
Autosomal dominant omodysplasia is caused by heterozygous mutations in FZD2. Most reported cases are de novo, with nonsense mutations in the C-terminal Dishevelled-interacting domain representing a mutational hotspot.
Autosomal dominant inheritance De novo rate: majority
Show evidence (2 references)
PMID:25759469 SUPPORT Human Clinical
"We identified a de novo mutation in FRIZZLED2 (FZD2) in the proband and her daughter that was not found in unaffected family members"
First identification of FZD2 as the causative gene for autosomal dominant omodysplasia.
PMID:29383834 SUPPORT Human Clinical
"Molecular analysis identified a de novo, heterozygous, nonsense mutation (c.1640C>A, p.S547*) in FZD2. The affected codon was next to the previously reported mutation (p.Trp548*)"
Confirms recurrent de novo nonsense FZD2 mutations in the C-terminal domain as the cause of autosomal dominant omodysplasia.

Subtypes

2
Autosomal Recessive Omodysplasia (GPC6-related) MONDO:0009779
The recessive form is caused by biallelic loss-of-function mutations in GPC6. It presents with severe generalized rhizomelic limb shortening affecting both upper and lower extremities, facial dysmorphism, and variable developmental delay. Fewer than 30 cases have been reported.
Autosomal Dominant Omodysplasia (FZD2-related) MONDO:0008123
The dominant form is caused by heterozygous mutations in FZD2. It is characterized by predominantly humeral shortening with relatively normal stature, short first metacarpals, and genitourinary anomalies. The phenotype overlaps with autosomal dominant Robinow syndrome.

Pathophysiology

3
GPC6 loss of function and impaired Hedgehog signaling
In the recessive form, loss-of-function mutations in GPC6 abolish the heparan sulfate binding site and the GPI membrane anchor, eliminating glypican-6 from the chondrocyte surface. GPC6 normally promotes Hedgehog signaling by binding to Hedgehog ligand through its core protein and to Patched-1 through its glycosaminoglycan chains, facilitating ligand-receptor interaction at the primary cilium. Loss of GPC6 reduces Hedgehog signaling in growth plate chondrocytes, impairing proliferative chondrocyte function and endochondral ossification.
Growth plate chondrocyte link
Endochondral ossification link ↓ DECREASED Smoothened signaling pathway link ↓ DECREASED
Show evidence (4 references)
PMID:19481194 SUPPORT Human Clinical
"All mutations cause truncation of the GPC6 protein and abolish both the HS-binding site and the GPI-bearing membrane-associated domain, and thus loss of function is predicted"
Demonstrates that all identified GPC6 mutations are loss-of-function, truncating both the heparan sulfate binding and membrane anchor domains.
PMID:28696225 SUPPORT Model Organism
"GPC6-null embryos display most of the abnormalities found in OMOD1 patients and that Hedgehog (Hh) signaling is significantly reduced in the long bones of these embryos"
GPC6 knockout mice recapitulate OMOD1 phenotype and demonstrate that reduced Hedgehog signaling in developing long bones is the key pathogenic mechanism.
PMID:28696225 SUPPORT Model Organism
"GPC6 stimulates Hh signaling by binding to Hh and Ptc1 at the cilium and increasing the interaction of the receptor and ligand"
Establishes the molecular mechanism by which GPC6 promotes Hedgehog signaling at the primary cilium.
+ 1 more reference
FZD2 dysfunction and impaired Wnt signaling
In the dominant form, heterozygous nonsense mutations in FZD2 impair the interaction of Frizzled-2 with Dishevelled, disrupting both canonical (beta-catenin-dependent) and non-canonical (planar cell polarity) Wnt signaling pathways in limb mesenchyme. This leads to shortened bone elements through defective chondrocyte elongation and orientation.
Growth plate chondrocyte link
Canonical Wnt signaling pathway link ↓ DECREASED Planar cell polarity pathway link ↓ DECREASED Endochondral ossification link ↓ DECREASED
Show evidence (4 references)
PMID:25759469 SUPPORT In Vitro
"we show reduced ability of this mutant form of FZD2 to interact with its downstream target DISHEVELLED. Furthermore, expressing the mutant form of FZD2 in vitro is not able to facilitate the cellular response to canonical Wnt signaling like wild-type FZD2"
Demonstrates that the FZD2 W548* mutation impairs Dishevelled interaction and canonical Wnt signaling in functional assays.
PMID:36867021 SUPPORT Model Organism
"Fzd2em1Smill mutant embryos displayed decreased canonical Wnt signaling in developing limb mesenchyme and disruption of digit chondrocyte elongation and orientation, which is controlled by the β-catenin-independent WNT5A/planar cell polarity (PCP) pathway"
Mouse model demonstrates that FZD2 mutations disrupt both canonical and non-canonical Wnt signaling in limb development, directly causing shortened bone elements.
PMID:36867021 SUPPORT Model Organism
"FZD2 controls limb development by mediating both canonical and non-canonical Wnt pathways and reveal causality of pathogenic FZD2 mutations in RS and OMOD2 patients"
Confirms FZD2 as causative for OMOD2 and shows dual pathway involvement.
+ 1 more reference
Impaired chondrocyte proliferation and long bone growth
The shared downstream consequence of both GPC6 and FZD2 deficiency is impaired growth plate chondrocyte function. Growth plate cartilage shows reduced chondrocyte proliferation and disorganized maturation, resulting in defective endochondral ossification with shortened, malformed long bones.
Growth plate chondrocyte link
Growth plate chondrocyte differentiation link ↓ DECREASED Endochondral bone growth link ↓ DECREASED
Show evidence (4 references)
PMID:19481194 SUPPORT Model Organism
"Expression studies in microdissected mouse growth plate revealed expression of Gpc6 in proliferative chondrocytes"
Demonstrates GPC6 expression in the relevant cell type (proliferative growth plate chondrocytes), supporting the growth plate mechanism.
PMID:28696225 SUPPORT Model Organism
"Hedgehog (Hh) signaling is significantly reduced in the long bones of these embryos"
Reduced Hedgehog signaling in long bones of GPC6-null mice directly explains the limb shortening phenotype.
PMID:9508243 SUPPORT Human Clinical
"The pathological characteristics of the omodysplastic physeal plates were an expanded zone of proliferating cartilage and an increased number of closely packed, small chondrocytes"
Histomorphometric analysis of an omodysplastic fetus directly demonstrates growth plate chondrocyte abnormalities, with compensatory hyperplasia of small chondrocytes.
+ 1 more reference

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Omodysplasia Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.

Phenotypes

22
Cardiovascular 2
Facial midline hemangioma Midline facial capillary hemangioma (HP:0007601)
Show evidence (1 reference)
PMID:14566439 SUPPORT Human Clinical
"midline haemangiomas in infants"
Midline hemangiomas in infancy are described as a feature of the recessive form.
Congenital heart defect Abnormal heart morphology (HP:0001627)
Show evidence (1 reference)
PMID:8209882 SUPPORT Human Clinical
"Two sibs with omodysplasia were born to phenotypically normal but consanguineous parents. They had severe micromelic dwarfism, facial anomalies, and mental retardation. One had a congenital heart defect"
Documents congenital heart defect in a molecularly confirmed recessive family, supporting inclusion as an associated but apparently uncommon extraskeletal manifestation.
Ear 1
Low-set ears Low-set ears (HP:0000369)
Show evidence (1 reference)
PMID:29383834 SUPPORT Human Clinical
"He presented with rhizomelic short stature with elbow restriction, mild facial dysmorphism (depressed broad bridge, short nose, anteverted nostrils, long philtrum, and low-set ears), and genital hypoplasia"
Supports low-set ears as part of the OMOD2 facial phenotype.
Genitourinary 1
Cryptorchidism Cryptorchidism (HP:0000028)
Show evidence (1 reference)
PMID:14566439 SUPPORT Human Clinical
"cryptorchidism in males"
Cryptorchidism is described as a feature in males with the recessive form.
Head and Neck 7
Depressed nasal bridge Depressed nasal bridge (HP:0005280)
Show evidence (2 references)
PMID:14566439 SUPPORT Human Clinical
"a distinct face with a short nose, depressed nasal bridge, long philtrum"
Supports depressed nasal bridge in recessive omodysplasia.
PMID:2729357 SUPPORT Human Clinical
"Three cases of a new congenital bone disorder associating facial anomalies (depressed nasal bridge, broad base of the nose, long philtrum) with short humeri"
Original dominant omodysplasia cases also showed a depressed nasal bridge.
Long philtrum Long philtrum (HP:0000343)
Show evidence (2 references)
PMID:14566439 SUPPORT Human Clinical
"a distinct face with a short nose, depressed nasal bridge, long philtrum"
Supports long philtrum in recessive omodysplasia.
PMID:29383834 SUPPORT Human Clinical
"craniofacial dysmorphism (frontal bossing, depressed nasal bridge, bifid nasal tip, and long philtrum)"
Confirms that long philtrum is also part of the dominant OMOD2 facial phenotype.
Frontal bossing Frontal bossing (HP:0002007)
Show evidence (1 reference)
PMID:29383834 SUPPORT Human Clinical
"craniofacial dysmorphism (frontal bossing, depressed nasal bridge, bifid nasal tip, and long philtrum)"
Frontal bossing is listed among the defining craniofacial features of OMOD2.
Short nose Short nose (HP:0003196)
Show evidence (2 references)
PMID:14566439 SUPPORT Human Clinical
"a distinct face with a short nose, depressed nasal bridge, long philtrum"
Supports short nose in recessive omodysplasia.
PMID:29383834 SUPPORT Human Clinical
"He presented with rhizomelic short stature with elbow restriction, mild facial dysmorphism (depressed broad bridge, short nose, anteverted nostrils, long philtrum, and low-set ears), and genital hypoplasia"
Confirms short nose in a molecularly confirmed dominant case.
Anteverted nares Anteverted nares (HP:0000463)
Show evidence (1 reference)
PMID:29383834 SUPPORT Human Clinical
"He presented with rhizomelic short stature with elbow restriction, mild facial dysmorphism (depressed broad bridge, short nose, anteverted nostrils, long philtrum, and low-set ears), and genital hypoplasia"
Directly supports anteverted nares in FZD2-related dominant omodysplasia.
Cleft lip Cleft lip (HP:0410030)
Show evidence (2 references)
PMID:29230162 SUPPORT Human Clinical
"We described a heterozygous de novo mutation (G434V) in the frizzled class receptor 2 (FZD2) gene in a patient with distinct facial features including hypertelorism, bilateral cleft lip/palate, short nose with a broad nasal bridge, microretrognathia"
Documents cleft lip in a molecularly confirmed dominant case.
PMID:41022130 SUPPORT Human Clinical
"We describe a prenatally detected case with shortened upper extremities, cleft lip and palate and suspected genital hypoplasia"
Additional recent prenatal case confirms that cleft lip can be part of the OMOD2 spectrum.
Cleft palate Cleft palate (HP:0000175)
Show evidence (2 references)
PMID:29230162 SUPPORT Human Clinical
"We described a heterozygous de novo mutation (G434V) in the frizzled class receptor 2 (FZD2) gene in a patient with distinct facial features including hypertelorism, bilateral cleft lip/palate, short nose with a broad nasal bridge, microretrognathia"
Documents cleft palate in a molecularly confirmed dominant case.
PMID:41022130 SUPPORT Human Clinical
"We describe a prenatally detected case with shortened upper extremities, cleft lip and palate and suspected genital hypoplasia"
Additional recent prenatal case confirms that cleft palate can be part of the OMOD2 spectrum.
Limbs 4
Short humerus Short humerus (HP:0005792)
Show evidence (2 references)
PMID:2729357 SUPPORT Human Clinical
"Three cases of a new congenital bone disorder associating facial anomalies (depressed nasal bridge, broad base of the nose, long philtrum) with short humeri"
Original description of dominant omodysplasia identified short humeri as a defining skeletal feature.
PMID:29383834 SUPPORT Human Clinical
"Radiological examination in infancy showed short, broad humeri with relatively narrow distal ends"
Confirms shortened humeri with distal narrowing in molecularly confirmed OMOD2.
Short femur Short femur (HP:0003097)
Show evidence (2 references)
PMID:9508243 SUPPORT Human Clinical
"Second-semester ultrasonography of a female fetus documented short femora and humeri and dislocation of the radii"
Provides direct evidence that femoral shortening is part of the recessive phenotype and can be detected prenatally.
PMID:32655339 SUPPORT Human Clinical
"The pathognomonic radiological findings were distally tapered humeri and femora as well as severe proximal radioulnar diastasis"
Confirms the characteristic tapered femoral morphology in molecularly confirmed recessive omodysplasia.
Limited elbow extension Limited elbow extension (HP:0001377)
Show evidence (2 references)
PMID:14566439 SUPPORT Human Clinical
"Clinical features are rhizomelic dwarfism with limited extension of elbows and knees"
Supports elbow extension limitation in recessive omodysplasia.
PMID:29383834 SUPPORT Human Clinical
"He presented with rhizomelic short stature with elbow restriction, mild facial dysmorphism"
Confirms elbow restriction in a molecularly confirmed dominant case.
Short first metacarpal Short 1st metacarpal (HP:0010034)
Show evidence (2 references)
PMID:25759469 SUPPORT Human Clinical
"Autosomal dominant omodysplasia is a rare skeletal dysplasia characterized by short humeri, radial head dislocation, short first metacarpals, facial dysmorphism and genitourinary anomalies"
Establishes short first metacarpals as part of the core dominant phenotype.
PMID:29383834 SUPPORT Human Clinical
"Radiological examination in infancy showed short, broad humeri with relatively narrow distal ends, mildly broad femora, thick proximal ulnae with hypoplastic, dislocated proximal radii, and short first metacarpals"
Provides radiographic confirmation of first-metacarpal shortening in OMOD2.
Nervous System 1
Global developmental delay Global developmental delay (HP:0001263)
Show evidence (1 reference)
PMID:19481194 SUPPORT Human Clinical
"short-limbed short stature, craniofacial dysmorphism, and variable developmental delay"
Supports variable developmental delay in GPC6-related recessive omodysplasia.
Growth 2
Rhizomelic limb shortening Rhizomelia (HP:0008905)
Show evidence (2 references)
PMID:14566439 SUPPORT Human Clinical
"Clinical features are rhizomelic dwarfism with limited extension of elbows and knees and a distinct face with a short nose, depressed nasal bridge, long philtrum, midline haemangiomas in infants and cryptorchidism in males"
Supports rhizomelic limb shortening as a hallmark of recessive omodysplasia.
PMID:29383834 SUPPORT Human Clinical
"The proband was a 16-year-old boy, who has been followed from infancy to adolescence. He presented with rhizomelic short stature with elbow restriction"
Confirms that rhizomelic shortening can also occur in FZD2-related dominant omodysplasia.
Context-specific annotations (1)
OMOD1 Onset: ANTENATAL
Show evidence (1 reference)
PMID:9508243 SUPPORT Human Clinical
"Second-semester ultrasonography of a female fetus documented short femora and humeri and dislocation of the radii"
Demonstrates antenatal manifestation of proximal long-bone shortening in recessive omodysplasia.
Disproportionate short-limb short stature Disproportionate short-limb short stature (HP:0008873)
Show evidence (1 reference)
PMID:19481194 SUPPORT Human Clinical
"autosomal-recessive omodysplasia, a genetic condition characterized by short-limbed short stature, craniofacial dysmorphism, and variable developmental delay"
Supports disproportionate short-limb short stature as a defining feature of the recessive form.
Other 4
Proximal radial head dislocation Proximal radial head dislocation (HP:0005070)
Show evidence (2 references)
PMID:14566439 SUPPORT Human Clinical
"Radiological findings are distal hypoplasia of the short humerus and femur with characteristic radial dislocation and radioulnar diastasis"
Identifies radial head dislocation with radioulnar diastasis as a characteristic radiologic feature of recessive omodysplasia.
PMID:25759469 SUPPORT Human Clinical
"Autosomal dominant omodysplasia is a rare skeletal dysplasia characterized by short humeri, radial head dislocation, short first metacarpals, facial dysmorphism and genitourinary anomalies"
Confirms that radial head dislocation is also part of the dominant FZD2-related phenotype.
Context-specific annotations (1)
OMOD1 Onset: ANTENATAL
Show evidence (1 reference)
PMID:9508243 SUPPORT Human Clinical
"Second-semester ultrasonography of a female fetus documented short femora and humeri and dislocation of the radii"
Shows antenatal detection of the forearm/elbow dislocation pattern in recessive omodysplasia.
Limited knee extension Limited knee extension (HP:0003066)
Show evidence (2 references)
PMID:14566439 SUPPORT Human Clinical
"Clinical features are rhizomelic dwarfism with limited extension of elbows and knees"
Directly supports limitation of knee extension in recessive omodysplasia.
PMID:32655339 SUPPORT Human Clinical
"Affected individuals manifest with rhizomelic short stature, decreased mobility of elbow and knee joints as well as craniofacial anomalies"
Confirms recurrent knee-joint mobility limitation in molecularly confirmed GPC6-related disease.
Bifid nasal tip Bifid nasal tip (HP:0000456)
Show evidence (1 reference)
PMID:29383834 SUPPORT Human Clinical
"craniofacial dysmorphism (frontal bossing, depressed nasal bridge, bifid nasal tip, and long philtrum)"
Directly supports bifid nasal tip in dominant omodysplasia.
External genital hypoplasia External genital hypoplasia (HP:0003241)
Show evidence (2 references)
PMID:29383834 SUPPORT Human Clinical
"rhizomelic short stature with elbow restriction, mild facial dysmorphism (depressed broad bridge, short nose, anteverted nostrils, long philtrum, and low-set ears), and genital hypoplasia"
Supports genital hypoplasia in a molecularly confirmed dominant case.
PMID:12210345 SUPPORT Human Clinical
"Her son had ambiguous genitalia and similar skeletal manifestations as his mother. A comparison to other known and suspected cases of dominant omodysplasia is presented. Our observations confirm the existence of a dominant variant of omodysplasia, document genital hypoplasia as an important..."
Independent dominant family confirms that male genital hypoplasia is an important feature and can present as ambiguous genitalia.
🧬

Genetic Associations

2
GPC6 mutations
Autosomal recessive
Show evidence (3 references)
PMID:19481194 SUPPORT Human Clinical
"autosomal-recessive omodysplasia, a genetic condition characterized by short-limbed short stature, craniofacial dysmorphism, and variable developmental delay, maps to chromosome 13 (13q31.1-q32.2) and is caused by point mutations or by larger genomic rearrangements in glypican 6 (GPC6)"
Maps the disease locus and identifies the causative gene with the spectrum of mutation types.
PMID:32655339 SUPPORT Human Clinical
"A homozygous deletion of exon 6 in the GPC6 gene was detected"
Confirms that larger genomic rearrangements (exon deletions) in GPC6 also cause the recessive form.
PMID:37353964 SUPPORT Human Clinical
"All affected individuals were found to have homozygous missense variants in GPC6: c.511 C>T (p.Arg171Trp)"
Identifies a hypomorphic GPC6 missense variant causing a milder skeletal dysplasia phenotype, expanding the mutation spectrum beyond truncating mutations.
FZD2 mutations
Autosomal dominant
Show evidence (4 references)
PMID:25759469 SUPPORT Human Clinical
"The FZD2 mutation (c.1644G>A) changes a tryptophan residue at amino acid 548 to a premature stop (p.Trp548*)"
First identification of the p.Trp548* nonsense mutation in FZD2 as the cause of autosomal dominant omodysplasia.
PMID:29383834 SUPPORT Human Clinical
"Molecular analysis identified a de novo, heterozygous, nonsense mutation (c.1640C>A, p.S547*) in FZD2. The affected codon was next to the previously reported mutation (p.Trp548*)"
Second FZD2 nonsense mutation at an adjacent codon confirms a mutational hotspot in the C-terminal Dishevelled-interacting domain.
PMID:30455931 SUPPORT Human Clinical
"two patients with autosomal dominant omodysplasia and mutations in the FZD2 gene. The mutations identified have been recently reported, suggesting the possibility of recurrent mutations"
Additional unrelated patients with FZD2 mutations support recurrence at the same hotspot.
+ 1 more reference
💊

Treatments

3
Orthopedic surgical management
Action: Orthopedic surgical management Ontology label: surgical procedure MAXO:0000004
Surgical intervention for management of radial head dislocation and other skeletal deformities. Limb-lengthening procedures may be considered in severe cases.
Physical therapy
Action: Physical therapy Ontology label: physical therapy MAXO:0000011
Rehabilitation to maintain and improve joint range of motion, particularly at the elbows and knees where restricted extension is common.
Genetic counseling
Action: Genetic counseling Ontology label: genetic counseling MAXO:0000079
Genetic counseling for families, particularly to distinguish between the autosomal recessive and autosomal dominant forms and to inform recurrence risk assessment.
{ }

Source YAML

click to show
name: Omodysplasia
creation_date: "2026-04-02T12:00:00Z"
updated_date: "2026-04-19T02:26:30Z"
category: Mendelian
description: >
  Omodysplasia is a rare skeletal dysplasia characterized by severe rhizomelic
  shortening of the limbs, particularly of the humeri and femora, with distal
  tapering giving a club-like long bone morphology. Craniofacial features include
  frontal bossing, depressed nasal bridge, short nose with anteverted nares, and
  a long philtrum. Two genetic forms are recognized: an autosomal recessive form
  (OMOD1) caused by loss-of-function mutations in GPC6 encoding glypican-6, a
  heparan sulfate proteoglycan that stimulates Hedgehog signaling in growth plate
  chondrocytes; and an autosomal dominant form (OMOD2) caused by heterozygous
  mutations in FZD2 encoding Frizzled-2, a Wnt receptor that mediates both
  canonical and non-canonical Wnt signaling in limb development. The recessive
  form is more severe with generalized limb shortening, while the dominant form
  shows preferential humeral involvement with relatively preserved stature.
disease_term:
  preferred_term: omodysplasia
  term:
    id: MONDO:0017136
    label: omodysplasia
parents:
- Skeletal Dysplasia
- Rhizomelic Limb Shortening Syndrome
has_subtypes:
- name: OMOD1
  display_name: Autosomal Recessive Omodysplasia (GPC6-related)
  description: >
    The recessive form is caused by biallelic loss-of-function mutations in GPC6.
    It presents with severe generalized rhizomelic limb shortening affecting both
    upper and lower extremities, facial dysmorphism, and variable developmental
    delay. Fewer than 30 cases have been reported.
  subtype_term:
    preferred_term: autosomal recessive omodysplasia
    term:
      id: MONDO:0009779
      label: autosomal recessive omodysplasia
- name: OMOD2
  display_name: Autosomal Dominant Omodysplasia (FZD2-related)
  description: >
    The dominant form is caused by heterozygous mutations in FZD2. It is
    characterized by predominantly humeral shortening with relatively normal
    stature, short first metacarpals, and genitourinary anomalies. The phenotype
    overlaps with autosomal dominant Robinow syndrome.
  subtype_term:
    preferred_term: autosomal dominant omodysplasia
    term:
      id: MONDO:0008123
      label: autosomal dominant omodysplasia
inheritance:
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >
    Autosomal recessive omodysplasia is caused by biallelic mutations in GPC6,
    including point mutations and larger genomic rearrangements. Parental
    consanguinity is common among reported families.
  evidence:
  - reference: PMID:19481194
    reference_title: "Mutations in the heparan-sulfate proteoglycan glypican 6 (GPC6) impair endochondral ossification and cause recessive omodysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      autosomal-recessive omodysplasia, a genetic condition characterized by
      short-limbed short stature, craniofacial dysmorphism, and variable
      developmental delay, maps to chromosome 13 (13q31.1-q32.2) and is caused
      by point mutations or by larger genomic rearrangements in glypican 6 (GPC6)
    explanation: >-
      Identifies GPC6 as the causative gene for autosomal recessive omodysplasia
      via linkage mapping and mutation analysis.
- name: Autosomal dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  de_novo_rate: "majority"
  description: >
    Autosomal dominant omodysplasia is caused by heterozygous mutations in FZD2.
    Most reported cases are de novo, with nonsense mutations in the C-terminal
    Dishevelled-interacting domain representing a mutational hotspot.
  evidence:
  - reference: PMID:25759469
    reference_title: "A mutation in FRIZZLED2 impairs Wnt signaling and causes autosomal dominant omodysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified a de novo mutation in FRIZZLED2 (FZD2) in the proband and
      her daughter that was not found in unaffected family members
    explanation: >-
      First identification of FZD2 as the causative gene for autosomal dominant
      omodysplasia.
  - reference: PMID:29383834
    reference_title: "Nonsense mutations in FZD2 cause autosomal-dominant omodysplasia: Robinow syndrome-like phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Molecular analysis identified a de novo, heterozygous, nonsense mutation
      (c.1640C>A, p.S547*) in FZD2. The affected codon was next to the
      previously reported mutation (p.Trp548*)
    explanation: >-
      Confirms recurrent de novo nonsense FZD2 mutations in the C-terminal
      domain as the cause of autosomal dominant omodysplasia.
pathophysiology:
- name: GPC6 loss of function and impaired Hedgehog signaling
  description: >
    In the recessive form, loss-of-function mutations in GPC6 abolish the
    heparan sulfate binding site and the GPI membrane anchor, eliminating
    glypican-6 from the chondrocyte surface. GPC6 normally promotes Hedgehog
    signaling by binding to Hedgehog ligand through its core protein and to
    Patched-1 through its glycosaminoglycan chains, facilitating ligand-receptor
    interaction at the primary cilium. Loss of GPC6 reduces Hedgehog signaling in
    growth plate chondrocytes, impairing proliferative chondrocyte function and
    endochondral ossification.
  cell_types:
  - preferred_term: Growth plate chondrocyte
    term:
      id: CL:1000217
      label: growth plate cartilage chondrocyte
  biological_processes:
  - preferred_term: Endochondral ossification
    term:
      id: GO:0001958
      label: endochondral ossification
    modifier: DECREASED
  - preferred_term: Smoothened signaling pathway
    term:
      id: GO:0007224
      label: smoothened signaling pathway
    modifier: DECREASED
  gene:
    preferred_term: GPC6
    description: >-
      Glypican-6, a GPI-anchored heparan sulfate proteoglycan expressed in
      proliferative chondrocytes that stimulates Hedgehog signaling by
      facilitating Hedgehog-Patched interaction at the primary cilium.
    modifier: DECREASED
    term:
      id: hgnc:4454
      label: GPC6
  evidence:
  - reference: PMID:19481194
    reference_title: "Mutations in the heparan-sulfate proteoglycan glypican 6 (GPC6) impair endochondral ossification and cause recessive omodysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All mutations cause truncation of the GPC6 protein and abolish both the
      HS-binding site and the GPI-bearing membrane-associated domain, and thus
      loss of function is predicted
    explanation: >-
      Demonstrates that all identified GPC6 mutations are loss-of-function,
      truncating both the heparan sulfate binding and membrane anchor domains.
  - reference: PMID:28696225
    reference_title: "Glypican-6 promotes the growth of developing long bones by stimulating Hedgehog signaling."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      GPC6-null embryos display most of the abnormalities found in OMOD1
      patients and that Hedgehog (Hh) signaling is significantly reduced in
      the long bones of these embryos
    explanation: >-
      GPC6 knockout mice recapitulate OMOD1 phenotype and demonstrate that
      reduced Hedgehog signaling in developing long bones is the key
      pathogenic mechanism.
  - reference: PMID:28696225
    reference_title: "Glypican-6 promotes the growth of developing long bones by stimulating Hedgehog signaling."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      GPC6 stimulates Hh signaling by binding to Hh and Ptc1 at the cilium and
      increasing the interaction of the receptor and ligand
    explanation: >-
      Establishes the molecular mechanism by which GPC6 promotes Hedgehog
      signaling at the primary cilium.
  - reference: PMID:28869591
    reference_title: "Identification of 153 new loci associated with heel bone mineral density and functional involvement of GPC6 in osteoporosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The results implicate GPC6 as a novel determinant of BMD
    explanation: >-
      Large-scale GWAS identifies GPC6 as a determinant of bone mineral density
      in the general population, supporting its broader role in skeletal
      biology beyond omodysplasia.
  downstream:
  - target: Impaired chondrocyte proliferation and long bone growth
- name: FZD2 dysfunction and impaired Wnt signaling
  description: >
    In the dominant form, heterozygous nonsense mutations in FZD2 impair the
    interaction of Frizzled-2 with Dishevelled, disrupting both canonical
    (beta-catenin-dependent) and non-canonical (planar cell polarity) Wnt
    signaling pathways in limb mesenchyme. This leads to shortened bone elements
    through defective chondrocyte elongation and orientation.
  cell_types:
  - preferred_term: Growth plate chondrocyte
    term:
      id: CL:1000217
      label: growth plate cartilage chondrocyte
  biological_processes:
  - preferred_term: Canonical Wnt signaling pathway
    term:
      id: GO:0060070
      label: canonical Wnt signaling pathway
    modifier: DECREASED
  - preferred_term: Planar cell polarity pathway
    term:
      id: GO:0060071
      label: Wnt signaling pathway, planar cell polarity pathway
    modifier: DECREASED
  - preferred_term: Endochondral ossification
    term:
      id: GO:0001958
      label: endochondral ossification
    modifier: DECREASED
  gene:
    preferred_term: FZD2
    description: >-
      Frizzled-2, a Wnt receptor that mediates both canonical and non-canonical
      Wnt signaling pathways in limb development. Nonsense mutations impair
      interaction with Dishevelled.
    modifier: DECREASED
    term:
      id: hgnc:4040
      label: FZD2
  evidence:
  - reference: PMID:25759469
    reference_title: "A mutation in FRIZZLED2 impairs Wnt signaling and causes autosomal dominant omodysplasia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      we show reduced ability of this mutant form of FZD2 to interact with its
      downstream target DISHEVELLED. Furthermore, expressing the mutant form of
      FZD2 in vitro is not able to facilitate the cellular response to canonical
      Wnt signaling like wild-type FZD2
    explanation: >-
      Demonstrates that the FZD2 W548* mutation impairs Dishevelled interaction
      and canonical Wnt signaling in functional assays.
  - reference: PMID:36867021
    reference_title: "FZD2 regulates limb development by mediating β-catenin-dependent and -independent Wnt signaling pathways."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Fzd2em1Smill mutant embryos displayed decreased canonical Wnt signaling in
      developing limb mesenchyme and disruption of digit chondrocyte elongation
      and orientation, which is controlled by the β-catenin-independent
      WNT5A/planar cell polarity (PCP) pathway
    explanation: >-
      Mouse model demonstrates that FZD2 mutations disrupt both canonical and
      non-canonical Wnt signaling in limb development, directly causing
      shortened bone elements.
  - reference: PMID:36867021
    reference_title: "FZD2 regulates limb development by mediating β-catenin-dependent and -independent Wnt signaling pathways."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      FZD2 controls limb development by mediating both canonical and
      non-canonical Wnt pathways and reveal causality of pathogenic FZD2
      mutations in RS and OMOD2 patients
    explanation: >-
      Confirms FZD2 as causative for OMOD2 and shows dual pathway involvement.
  - reference: PMID:36967195
    reference_title: "Non-canonical WNT5A-ROR signaling: New perspectives on an ancient developmental pathway."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      mutations in each of these signaling components cause Robinow syndrome, a
      congenital disorder characterized by profound tissue morphogenetic
      abnormalities
    explanation: >-
      Review establishes that FZD2 is part of the core WNT5A-ROR-FZD-DVL
      non-canonical signaling module, and that mutations in any component of
      this pathway cause overlapping Robinow/omodysplasia phenotypes.
  downstream:
  - target: Impaired chondrocyte proliferation and long bone growth
- name: Impaired chondrocyte proliferation and long bone growth
  description: >
    The shared downstream consequence of both GPC6 and FZD2 deficiency is
    impaired growth plate chondrocyte function. Growth plate cartilage shows
    reduced chondrocyte proliferation and disorganized maturation, resulting in
    defective endochondral ossification with shortened, malformed long bones.
  cell_types:
  - preferred_term: Growth plate chondrocyte
    term:
      id: CL:1000217
      label: growth plate cartilage chondrocyte
  biological_processes:
  - preferred_term: Growth plate chondrocyte differentiation
    term:
      id: GO:0003418
      label: growth plate cartilage chondrocyte differentiation
    modifier: DECREASED
  - preferred_term: Endochondral bone growth
    term:
      id: GO:0003416
      label: endochondral bone growth
    modifier: DECREASED
  evidence:
  - reference: PMID:19481194
    reference_title: "Mutations in the heparan-sulfate proteoglycan glypican 6 (GPC6) impair endochondral ossification and cause recessive omodysplasia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Expression studies in microdissected mouse growth plate revealed expression
      of Gpc6 in proliferative chondrocytes
    explanation: >-
      Demonstrates GPC6 expression in the relevant cell type (proliferative
      growth plate chondrocytes), supporting the growth plate mechanism.
  - reference: PMID:28696225
    reference_title: "Glypican-6 promotes the growth of developing long bones by stimulating Hedgehog signaling."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Hedgehog (Hh) signaling is significantly reduced in the long bones of
      these embryos
    explanation: >-
      Reduced Hedgehog signaling in long bones of GPC6-null mice directly
      explains the limb shortening phenotype.
  - reference: PMID:9508243
    reference_title: "Autosomal-recessive omodysplasia: prenatal diagnosis and histomorphometric assessment of the physeal plates of the long bones."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The pathological characteristics of the omodysplastic physeal plates were
      an expanded zone of proliferating cartilage and an increased number of
      closely packed, small chondrocytes
    explanation: >-
      Histomorphometric analysis of an omodysplastic fetus directly
      demonstrates growth plate chondrocyte abnormalities, with compensatory
      hyperplasia of small chondrocytes.
  - reference: PMID:37353964
    reference_title: "Five siblings expand the spectrum of GPC6-related skeletal dysplasia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      the variant found in this family results in significantly reduced
      stimulation of Hh activity when compared to the wild-type GPC6 protein,
      however protein function is still present
    explanation: >-
      Hedgehog reporter assay demonstrates that GPC6 missense variant
      p.Arg171Trp causes reduced but not abolished Hh signaling, explaining
      the milder phenotype and confirming Hh as the key pathway.
phenotypes:
- category: Musculoskeletal
  name: Rhizomelic limb shortening
  description: >
    Proximal limb shortening is a core manifestation. In GPC6-related disease,
    both upper and lower limbs may be markedly involved, whereas FZD2-related
    disease can show upper-limb-predominant rhizomelia.
  phenotype_term:
    preferred_term: Rhizomelic limb shortening
    term:
      id: HP:0008905
      label: Rhizomelia
  evidence:
  - reference: PMID:14566439
    reference_title: "Recessive omodysplasia: five new cases and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical features are rhizomelic dwarfism with limited extension of elbows
      and knees and a distinct face with a short nose, depressed nasal bridge,
      long philtrum, midline haemangiomas in infants and cryptorchidism in males
    explanation: >-
      Supports rhizomelic limb shortening as a hallmark of recessive
      omodysplasia.
  - reference: PMID:29383834
    reference_title: "Nonsense mutations in FZD2 cause autosomal-dominant omodysplasia: Robinow syndrome-like phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The proband was a 16-year-old boy, who has been followed from infancy to
      adolescence. He presented with rhizomelic short stature with elbow
      restriction
    explanation: >-
      Confirms that rhizomelic shortening can also occur in FZD2-related
      dominant omodysplasia.
  phenotype_contexts:
  - subtype: OMOD1
    onset:
      onset_category: ANTENATAL
      notes: Second-semester ultrasonography documented short humeri and femora prenatally.
    evidence:
    - reference: PMID:9508243
      reference_title: "Autosomal-recessive omodysplasia: prenatal diagnosis and histomorphometric assessment of the physeal plates of the long bones."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Second-semester ultrasonography of a female fetus documented short
        femora and humeri and dislocation of the radii
      explanation: >-
        Demonstrates antenatal manifestation of proximal long-bone shortening in
        recessive omodysplasia.
- category: Musculoskeletal
  name: Short humerus
  description: >
    The humeri are short and often show distal tapering or relative
    broadening/undermodeling on radiographs.
  phenotype_term:
    preferred_term: Short humerus
    term:
      id: HP:0005792
      label: Short humerus
  evidence:
  - reference: PMID:2729357
    reference_title: Omodysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Three cases of a new congenital bone disorder associating facial
      anomalies (depressed nasal bridge, broad base of the nose, long philtrum)
      with short humeri
    explanation: >-
      Original description of dominant omodysplasia identified short humeri as a
      defining skeletal feature.
  - reference: PMID:29383834
    reference_title: "Nonsense mutations in FZD2 cause autosomal-dominant omodysplasia: Robinow syndrome-like phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Radiological examination in infancy showed short, broad humeri with
      relatively narrow distal ends
    explanation: >-
      Confirms shortened humeri with distal narrowing in molecularly confirmed
      OMOD2.
- category: Musculoskeletal
  name: Short femur
  subtype: OMOD1
  description: >
    The femora are shortened in recessive omodysplasia and may show distal
    tapering or undermodeling.
  phenotype_term:
    preferred_term: Short femur
    term:
      id: HP:0003097
      label: Short femur
  evidence:
  - reference: PMID:9508243
    reference_title: "Autosomal-recessive omodysplasia: prenatal diagnosis and histomorphometric assessment of the physeal plates of the long bones."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Second-semester ultrasonography of a female fetus documented short
      femora and humeri and dislocation of the radii
    explanation: >-
      Provides direct evidence that femoral shortening is part of the recessive
      phenotype and can be detected prenatally.
  - reference: PMID:32655339
    reference_title: "Novel Clinical and Radiological Findings in a Family with Autosomal Recessive Omodysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The pathognomonic radiological findings were distally tapered humeri and
      femora as well as severe proximal radioulnar diastasis
    explanation: >-
      Confirms the characteristic tapered femoral morphology in molecularly
      confirmed recessive omodysplasia.
- category: Musculoskeletal
  name: Proximal radial head dislocation
  description: >
    Radial head dislocation is a characteristic elbow abnormality and is often
    accompanied by proximal radioulnar diastasis.
  phenotype_term:
    preferred_term: Proximal radial head dislocation
    term:
      id: HP:0005070
      label: Proximal radial head dislocation
  evidence:
  - reference: PMID:14566439
    reference_title: "Recessive omodysplasia: five new cases and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Radiological findings are distal hypoplasia of the short humerus and femur
      with characteristic radial dislocation and radioulnar diastasis
    explanation: >-
      Identifies radial head dislocation with radioulnar diastasis as a
      characteristic radiologic feature of recessive omodysplasia.
  - reference: PMID:25759469
    reference_title: "A mutation in FRIZZLED2 impairs Wnt signaling and causes autosomal dominant omodysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autosomal dominant omodysplasia is a rare skeletal dysplasia
      characterized by short humeri, radial head dislocation, short first
      metacarpals, facial dysmorphism and genitourinary anomalies
    explanation: >-
      Confirms that radial head dislocation is also part of the dominant
      FZD2-related phenotype.
  phenotype_contexts:
  - subtype: OMOD1
    onset:
      onset_category: ANTENATAL
      notes: Prenatal ultrasonography documented dislocation of the radii in a recessive case.
    evidence:
    - reference: PMID:9508243
      reference_title: "Autosomal-recessive omodysplasia: prenatal diagnosis and histomorphometric assessment of the physeal plates of the long bones."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Second-semester ultrasonography of a female fetus documented short
        femora and humeri and dislocation of the radii
      explanation: >-
        Shows antenatal detection of the forearm/elbow dislocation pattern in
        recessive omodysplasia.
- category: Musculoskeletal
  name: Limited elbow extension
  description: >
    Elbow motion is restricted, particularly extension, in both recessive and
    dominant disease.
  phenotype_term:
    preferred_term: Limited elbow extension
    term:
      id: HP:0001377
      label: Limited elbow extension
  evidence:
  - reference: PMID:14566439
    reference_title: "Recessive omodysplasia: five new cases and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical features are rhizomelic dwarfism with limited extension of elbows
      and knees
    explanation: >-
      Supports elbow extension limitation in recessive omodysplasia.
  - reference: PMID:29383834
    reference_title: "Nonsense mutations in FZD2 cause autosomal-dominant omodysplasia: Robinow syndrome-like phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      He presented with rhizomelic short stature with elbow restriction, mild
      facial dysmorphism
    explanation: >-
      Confirms elbow restriction in a molecularly confirmed dominant case.
- category: Musculoskeletal
  name: Limited knee extension
  subtype: OMOD1
  description: >
    Knee extension can be limited in the recessive form alongside the elbow
    contracture phenotype.
  phenotype_term:
    preferred_term: Limited knee extension
    term:
      id: HP:0003066
      label: Limited knee extension
  evidence:
  - reference: PMID:14566439
    reference_title: "Recessive omodysplasia: five new cases and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical features are rhizomelic dwarfism with limited extension of elbows
      and knees
    explanation: >-
      Directly supports limitation of knee extension in recessive omodysplasia.
  - reference: PMID:32655339
    reference_title: "Novel Clinical and Radiological Findings in a Family with Autosomal Recessive Omodysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Affected individuals manifest with rhizomelic short stature, decreased
      mobility of elbow and knee joints as well as craniofacial anomalies
    explanation: >-
      Confirms recurrent knee-joint mobility limitation in molecularly
      confirmed GPC6-related disease.
- category: Musculoskeletal
  name: Short first metacarpal
  subtype: OMOD2
  description: >
    Shortening of the first metacarpals is a characteristic hand finding in the
    dominant form.
  phenotype_term:
    preferred_term: Short first metacarpal
    term:
      id: HP:0010034
      label: Short 1st metacarpal
  evidence:
  - reference: PMID:25759469
    reference_title: "A mutation in FRIZZLED2 impairs Wnt signaling and causes autosomal dominant omodysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autosomal dominant omodysplasia is a rare skeletal dysplasia
      characterized by short humeri, radial head dislocation, short first
      metacarpals, facial dysmorphism and genitourinary anomalies
    explanation: >-
      Establishes short first metacarpals as part of the core dominant
      phenotype.
  - reference: PMID:29383834
    reference_title: "Nonsense mutations in FZD2 cause autosomal-dominant omodysplasia: Robinow syndrome-like phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Radiological examination in infancy showed short, broad humeri with
      relatively narrow distal ends, mildly broad femora, thick proximal ulnae
      with hypoplastic, dislocated proximal radii, and short first metacarpals
    explanation: >-
      Provides radiographic confirmation of first-metacarpal shortening in OMOD2.
- category: Musculoskeletal
  name: Disproportionate short-limb short stature
  subtype: OMOD1
  description: >
    Generalized short stature with disproportionate limb shortening is a major
    feature of recessive omodysplasia; stature can be near normal in dominant
    disease.
  phenotype_term:
    preferred_term: Disproportionate short-limb short stature
    term:
      id: HP:0008873
      label: Disproportionate short-limb short stature
  evidence:
  - reference: PMID:19481194
    reference_title: "Mutations in the heparan-sulfate proteoglycan glypican 6 (GPC6) impair endochondral ossification and cause recessive omodysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      autosomal-recessive omodysplasia, a genetic condition characterized by
      short-limbed short stature, craniofacial dysmorphism, and variable
      developmental delay
    explanation: >-
      Supports disproportionate short-limb short stature as a defining feature
      of the recessive form.
- category: Craniofacial
  name: Depressed nasal bridge
  description: >
    A depressed nasal bridge is part of the characteristic facial gestalt in
    both recessive and dominant reports.
  phenotype_term:
    preferred_term: Depressed nasal bridge
    term:
      id: HP:0005280
      label: Depressed nasal bridge
  evidence:
  - reference: PMID:14566439
    reference_title: "Recessive omodysplasia: five new cases and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a distinct face with a short nose, depressed nasal bridge, long philtrum
    explanation: >-
      Supports depressed nasal bridge in recessive omodysplasia.
  - reference: PMID:2729357
    reference_title: Omodysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Three cases of a new congenital bone disorder associating facial
      anomalies (depressed nasal bridge, broad base of the nose, long philtrum)
      with short humeri
    explanation: >-
      Original dominant omodysplasia cases also showed a depressed nasal bridge.
- category: Craniofacial
  name: Long philtrum
  description: >
    Long philtrum is part of the recurrent facial phenotype in both recessive
    and dominant omodysplasia.
  phenotype_term:
    preferred_term: Long philtrum
    term:
      id: HP:0000343
      label: Long philtrum
  evidence:
  - reference: PMID:14566439
    reference_title: "Recessive omodysplasia: five new cases and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a distinct face with a short nose, depressed nasal bridge, long philtrum
    explanation: >-
      Supports long philtrum in recessive omodysplasia.
  - reference: PMID:29383834
    reference_title: "Nonsense mutations in FZD2 cause autosomal-dominant omodysplasia: Robinow syndrome-like phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      craniofacial dysmorphism (frontal bossing, depressed nasal bridge, bifid
      nasal tip, and long philtrum)
    explanation: >-
      Confirms that long philtrum is also part of the dominant OMOD2 facial
      phenotype.
- category: Craniofacial
  name: Frontal bossing
  subtype: OMOD2
  description: >
    Frontal bossing is part of the Robinow-like craniofacial phenotype reported
    in dominant omodysplasia.
  phenotype_term:
    preferred_term: Frontal bossing
    term:
      id: HP:0002007
      label: Frontal bossing
  evidence:
  - reference: PMID:29383834
    reference_title: "Nonsense mutations in FZD2 cause autosomal-dominant omodysplasia: Robinow syndrome-like phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      craniofacial dysmorphism (frontal bossing, depressed nasal bridge, bifid
      nasal tip, and long philtrum)
    explanation: >-
      Frontal bossing is listed among the defining craniofacial features of OMOD2.
- category: Craniofacial
  name: Short nose
  description: >
    Short nose is part of the characteristic facial appearance in both forms,
    although the accompanying nasal configuration differs across reports.
  phenotype_term:
    preferred_term: Short nose
    term:
      id: HP:0003196
      label: Short nose
  evidence:
  - reference: PMID:14566439
    reference_title: "Recessive omodysplasia: five new cases and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a distinct face with a short nose, depressed nasal bridge, long philtrum
    explanation: >-
      Supports short nose in recessive omodysplasia.
  - reference: PMID:29383834
    reference_title: "Nonsense mutations in FZD2 cause autosomal-dominant omodysplasia: Robinow syndrome-like phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      He presented with rhizomelic short stature with elbow restriction, mild
      facial dysmorphism (depressed broad bridge, short nose, anteverted
      nostrils, long philtrum, and low-set ears), and genital hypoplasia
    explanation: >-
      Confirms short nose in a molecularly confirmed dominant case.
- category: Craniofacial
  name: Anteverted nares
  subtype: OMOD2
  description: >
    Anteverted nares are part of the reported dominant craniofacial phenotype.
  phenotype_term:
    preferred_term: Anteverted nares
    term:
      id: HP:0000463
      label: Anteverted nares
  evidence:
  - reference: PMID:29383834
    reference_title: "Nonsense mutations in FZD2 cause autosomal-dominant omodysplasia: Robinow syndrome-like phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      He presented with rhizomelic short stature with elbow restriction, mild
      facial dysmorphism (depressed broad bridge, short nose, anteverted
      nostrils, long philtrum, and low-set ears), and genital hypoplasia
    explanation: >-
      Directly supports anteverted nares in FZD2-related dominant omodysplasia.
- category: Craniofacial
  name: Bifid nasal tip
  subtype: OMOD2
  description: >
    Bifid nasal tip has been reported as part of the OMOD2 facial phenotype.
  phenotype_term:
    preferred_term: Bifid nasal tip
    term:
      id: HP:0000456
      label: Bifid nasal tip
  evidence:
  - reference: PMID:29383834
    reference_title: "Nonsense mutations in FZD2 cause autosomal-dominant omodysplasia: Robinow syndrome-like phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      craniofacial dysmorphism (frontal bossing, depressed nasal bridge, bifid
      nasal tip, and long philtrum)
    explanation: >-
      Directly supports bifid nasal tip in dominant omodysplasia.
- category: Craniofacial
  name: Low-set ears
  subtype: OMOD2
  description: >
    Low-set ears were described in a molecularly confirmed dominant case.
  phenotype_term:
    preferred_term: Low-set ears
    term:
      id: HP:0000369
      label: Low-set ears
  evidence:
  - reference: PMID:29383834
    reference_title: "Nonsense mutations in FZD2 cause autosomal-dominant omodysplasia: Robinow syndrome-like phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      He presented with rhizomelic short stature with elbow restriction, mild
      facial dysmorphism (depressed broad bridge, short nose, anteverted
      nostrils, long philtrum, and low-set ears), and genital hypoplasia
    explanation: >-
      Supports low-set ears as part of the OMOD2 facial phenotype.
- category: Craniofacial
  name: Cleft lip
  subtype: OMOD2
  description: >
    Orofacial clefting with cleft lip has been reported in a subset of
    molecularly confirmed FZD2-related cases.
  phenotype_term:
    preferred_term: Cleft lip
    term:
      id: HP:0410030
      label: Cleft lip
  evidence:
  - reference: PMID:29230162
    reference_title: "A Novel de novo FZD2 Mutation in a Patient with Autosomal Dominant Omodysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We described a heterozygous de novo mutation (G434V) in the frizzled
      class receptor 2 (FZD2) gene in a patient with distinct facial features
      including hypertelorism, bilateral cleft lip/palate, short nose with a
      broad nasal bridge, microretrognathia
    explanation: >-
      Documents cleft lip in a molecularly confirmed dominant case.
  - reference: PMID:41022130
    reference_title: "[Omodysplasia Type II - first publication of de novo Mutation in FZD2 Gene]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We describe a prenatally detected case with shortened upper extremities,
      cleft lip and palate and suspected genital hypoplasia
    explanation: >-
      Additional recent prenatal case confirms that cleft lip can be part of
      the OMOD2 spectrum.
- category: Craniofacial
  name: Cleft palate
  subtype: OMOD2
  description: >
    Cleft palate has been reported with FZD2-related dominant omodysplasia,
    usually alongside cleft lip.
  phenotype_term:
    preferred_term: Cleft palate
    term:
      id: HP:0000175
      label: Cleft palate
  evidence:
  - reference: PMID:29230162
    reference_title: "A Novel de novo FZD2 Mutation in a Patient with Autosomal Dominant Omodysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We described a heterozygous de novo mutation (G434V) in the frizzled
      class receptor 2 (FZD2) gene in a patient with distinct facial features
      including hypertelorism, bilateral cleft lip/palate, short nose with a
      broad nasal bridge, microretrognathia
    explanation: >-
      Documents cleft palate in a molecularly confirmed dominant case.
  - reference: PMID:41022130
    reference_title: "[Omodysplasia Type II - first publication of de novo Mutation in FZD2 Gene]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We describe a prenatally detected case with shortened upper extremities,
      cleft lip and palate and suspected genital hypoplasia
    explanation: >-
      Additional recent prenatal case confirms that cleft palate can be part of
      the OMOD2 spectrum.
- category: Dermatological
  name: Facial midline hemangioma
  subtype: OMOD1
  description: >
    Midline facial hemangiomas in infancy are reported in the recessive form.
  phenotype_term:
    preferred_term: Facial midline hemangioma
    term:
      id: HP:0007601
      label: Midline facial capillary hemangioma
  evidence:
  - reference: PMID:14566439
    reference_title: "Recessive omodysplasia: five new cases and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      midline haemangiomas in infants
    explanation: >-
      Midline hemangiomas in infancy are described as a feature of the
      recessive form.
- category: Genitourinary
  name: Cryptorchidism
  subtype: OMOD1
  description: >
    Cryptorchidism in males is a recurrent feature in the recessive form.
  phenotype_term:
    preferred_term: Cryptorchidism
    term:
      id: HP:0000028
      label: Cryptorchidism
  evidence:
  - reference: PMID:14566439
    reference_title: "Recessive omodysplasia: five new cases and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      cryptorchidism in males
    explanation: >-
      Cryptorchidism is described as a feature in males with the recessive form.
- category: Genitourinary
  name: External genital hypoplasia
  subtype: OMOD2
  description: >
    Hypoplastic male external genitalia are part of the dominant phenotype;
    ambiguous genitalia was reported in one affected boy.
  phenotype_term:
    preferred_term: External genital hypoplasia
    term:
      id: HP:0003241
      label: External genital hypoplasia
  evidence:
  - reference: PMID:29383834
    reference_title: "Nonsense mutations in FZD2 cause autosomal-dominant omodysplasia: Robinow syndrome-like phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      rhizomelic short stature with elbow restriction, mild facial dysmorphism
      (depressed broad bridge, short nose, anteverted nostrils, long philtrum,
      and low-set ears), and genital hypoplasia
    explanation: >-
      Supports genital hypoplasia in a molecularly confirmed dominant case.
  - reference: PMID:12210345
    reference_title: "Omodysplasia: an affected mother and son."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Her son had ambiguous genitalia and similar skeletal manifestations as
      his mother. A comparison to other known and suspected cases of dominant
      omodysplasia is presented. Our observations confirm the existence of a
      dominant variant of omodysplasia, document genital hypoplasia as an
      important feature of this syndrome in males
    explanation: >-
      Independent dominant family confirms that male genital hypoplasia is an
      important feature and can present as ambiguous genitalia.
- category: Cardiovascular
  name: Congenital heart defect
  subtype: OMOD1
  description: >
    Congenital heart defects have been reported in recessive omodysplasia, but
    current evidence supports them as an uncommon associated finding rather than
    a core diagnostic feature.
  phenotype_term:
    preferred_term: Congenital heart defect
    term:
      id: HP:0001627
      label: Abnormal heart morphology
  evidence:
  - reference: PMID:8209882
    reference_title: "Parental consanguinity in two sibs with omodysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Two sibs with omodysplasia were born to phenotypically normal but
      consanguineous parents. They had severe micromelic dwarfism, facial
      anomalies, and mental retardation. One had a congenital heart defect
    explanation: >-
      Documents congenital heart defect in a molecularly confirmed recessive
      family, supporting inclusion as an associated but apparently uncommon
      extraskeletal manifestation.
- category: Neurological
  name: Global developmental delay
  subtype: OMOD1
  description: >
    Neurodevelopmental delay has been reported variably in recessive
    omodysplasia; current evidence does not support treating intellectual
    disability as a consistent dominant-feature claim.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:19481194
    reference_title: "Mutations in the heparan-sulfate proteoglycan glypican 6 (GPC6) impair endochondral ossification and cause recessive omodysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      short-limbed short stature, craniofacial dysmorphism, and variable
      developmental delay
    explanation: >-
      Supports variable developmental delay in GPC6-related recessive
      omodysplasia.
genetic:
- name: GPC6 mutations
  subtype: OMOD1
  gene_term:
    preferred_term: GPC6
    term:
      id: hgnc:4454
      label: GPC6
  inheritance:
  - name: Autosomal recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  features: >-
    Biallelic loss-of-function mutations including nonsense mutations, splice site
    mutations, and larger genomic rearrangements such as exon deletions. Most
    identified mutations truncate the GPC6 protein. Hypomorphic missense variants
    (e.g. p.Arg171Trp) have been reported with a milder phenotype, expanding the
    genotype-phenotype spectrum.
  evidence:
  - reference: PMID:19481194
    reference_title: "Mutations in the heparan-sulfate proteoglycan glypican 6 (GPC6) impair endochondral ossification and cause recessive omodysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      autosomal-recessive omodysplasia, a genetic condition characterized by
      short-limbed short stature, craniofacial dysmorphism, and variable
      developmental delay, maps to chromosome 13 (13q31.1-q32.2) and is caused
      by point mutations or by larger genomic rearrangements in glypican 6 (GPC6)
    explanation: >-
      Maps the disease locus and identifies the causative gene with the
      spectrum of mutation types.
  - reference: PMID:32655339
    reference_title: "Novel Clinical and Radiological Findings in a Family with Autosomal Recessive Omodysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A homozygous deletion of exon 6 in the GPC6 gene was detected
    explanation: >-
      Confirms that larger genomic rearrangements (exon deletions) in GPC6
      also cause the recessive form.
  - reference: PMID:37353964
    reference_title: "Five siblings expand the spectrum of GPC6-related skeletal dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All affected individuals were found to have homozygous missense variants
      in GPC6: c.511 C>T (p.Arg171Trp)
    explanation: >-
      Identifies a hypomorphic GPC6 missense variant causing a milder skeletal
      dysplasia phenotype, expanding the mutation spectrum beyond truncating
      mutations.
- name: FZD2 mutations
  subtype: OMOD2
  gene_term:
    preferred_term: FZD2
    term:
      id: hgnc:4040
      label: FZD2
  inheritance:
  - name: Autosomal dominant
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
  features: >-
    Heterozygous mutations in FZD2 including nonsense mutations in the C-terminal
    Dishevelled-interacting domain (p.Trp548*, p.Ser547*) and missense mutations
    (p.Gly434Val) affecting protein function. Most cases are de novo.
  evidence:
  - reference: PMID:25759469
    reference_title: "A mutation in FRIZZLED2 impairs Wnt signaling and causes autosomal dominant omodysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The FZD2 mutation (c.1644G>A) changes a tryptophan residue at amino acid
      548 to a premature stop (p.Trp548*)
    explanation: >-
      First identification of the p.Trp548* nonsense mutation in FZD2 as the
      cause of autosomal dominant omodysplasia.
  - reference: PMID:29383834
    reference_title: "Nonsense mutations in FZD2 cause autosomal-dominant omodysplasia: Robinow syndrome-like phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Molecular analysis identified a de novo, heterozygous, nonsense mutation
      (c.1640C>A, p.S547*) in FZD2. The affected codon was next to the
      previously reported mutation (p.Trp548*)
    explanation: >-
      Second FZD2 nonsense mutation at an adjacent codon confirms a mutational
      hotspot in the C-terminal Dishevelled-interacting domain.
  - reference: PMID:30455931
    reference_title: "Two unrelated patients with autosomal dominant omodysplasia and FRIZZLED2 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      two patients with autosomal dominant omodysplasia and mutations in the
      FZD2 gene. The mutations identified have been recently reported,
      suggesting the possibility of recurrent mutations
    explanation: >-
      Additional unrelated patients with FZD2 mutations support recurrence at
      the same hotspot.
  - reference: PMID:29230162
    reference_title: "A Novel de novo FZD2 Mutation in a Patient with Autosomal Dominant Omodysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a heterozygous de novo mutation (G434V) in the frizzled class receptor 2
      (FZD2) gene in a patient with distinct facial features including
      hypertelorism, bilateral cleft lip/palate, short nose with a broad nasal
      bridge, microretrognathia, and bilateral shortness of the upper limbs
    explanation: >-
      Identifies a missense FZD2 mutation (G434V) distinct from the C-terminal
      nonsense hotspot, expanding the mutation spectrum to include missense
      variants and broadening the phenotypic range to include cleft lip/palate.
animal_models:
- species: Mouse
  genotype: Gpc6 knockout
  description: >
    GPC6-null mice recapitulate the skeletal phenotype of autosomal recessive
    omodysplasia, with shortened long bones and significantly reduced Hedgehog
    signaling in developing long bones.
  genes:
  - preferred_term: GPC6
    term:
      id: hgnc:4454
      label: GPC6
  associated_phenotypes:
  - Short limbs
  - Reduced Hedgehog signaling in long bones
  evidence:
  - reference: PMID:28696225
    reference_title: "Glypican-6 promotes the growth of developing long bones by stimulating Hedgehog signaling."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      GPC6-null embryos display most of the abnormalities found in OMOD1
      patients and that Hedgehog (Hh) signaling is significantly reduced in
      the long bones of these embryos
    explanation: >-
      GPC6 knockout mouse validates the loss-of-function mechanism and
      directly models the human recessive phenotype.
- species: Mouse
  genotype: Fzd2em1Smill (single-nucleotide insertion causing frameshift)
  description: >
    Fzd2 mutant mice harboring a frameshift mutation in the final
    Dishevelled-interacting domain develop shortened limbs resembling human
    dominant omodysplasia and Robinow syndrome, with decreased canonical Wnt
    signaling in limb mesenchyme and disrupted chondrocyte polarity.
  genes:
  - preferred_term: FZD2
    term:
      id: hgnc:4040
      label: FZD2
  associated_phenotypes:
  - Short limbs
  - Decreased canonical Wnt signaling in limb mesenchyme
  - Disrupted chondrocyte elongation and orientation
  evidence:
  - reference: PMID:36867021
    reference_title: "FZD2 regulates limb development by mediating β-catenin-dependent and -independent Wnt signaling pathways."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Fzd2em1Smill mutant mice had shortened limbs, resembling those of RS and
      OMOD2 patients, indicating that FZD2 mutations are causative
    explanation: >-
      Fzd2 frameshift mouse model recapitulates the shortened limb phenotype
      of dominant omodysplasia, confirming causality.
prevalence:
- population: Global
  percentage: Unknown
  notes: >-
    Omodysplasia is extremely rare. Fewer than 20 cases of the recessive form
    had been reported by 2004, and approximately 10 cases of the dominant form
    had been reported by 2022.
  evidence:
  - reference: PMID:14566439
    reference_title: "Recessive omodysplasia: five new cases and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fewer than 20 cases have been reported in the literature so far
    explanation: >-
      Establishes the extreme rarity of the recessive form with fewer than
      20 published cases as of 2004.
  - reference: PMID:35937024
    reference_title: "Dominant omodysplasia-A sporadic case-A new case report and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ten cases of the autosomal dominant type of this disease have been
      reported
    explanation: >-
      Documents the rarity of the dominant form with approximately 10 reported
      cases as of 2022.
diagnosis:
- name: Clinical, Radiographic, and Molecular Diagnosis
  description: >-
    Omodysplasia is diagnosed from short-limbed short stature with severe
    proximal (rhizomelic) limb shortening, characteristic facial dysmorphism,
    and radiographic findings, and is subtyped by molecular genetic testing:
    autosomal recessive omodysplasia from biallelic GPC6 variants and
    autosomal dominant omodysplasia from heterozygous FZD2 variants.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: MAXO:0000533
      label: molecular genetic testing
  evidence:
  - reference: PMID:19481194
    reference_title: "Mutations in the heparan-sulfate proteoglycan glypican 6 (GPC6) impair endochondral ossification and cause recessive omodysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "autosomal-recessive omodysplasia, a genetic condition characterized by short-limbed short stature, craniofacial dysmorphism, and variable developmental delay, maps to chromosome 13 (13q31.1-q32.2) and is caused by point mutations or by larger genomic rearrangements in glypican 6 (GPC6)"
    explanation: >-
      Defines the clinical features and GPC6 molecular basis of autosomal recessive omodysplasia.
  - reference: PMID:25759469
    reference_title: "A mutation in FRIZZLED2 impairs Wnt signaling and causes autosomal dominant omodysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identified a de novo mutation in FRIZZLED2 (FZD2) in the proband and her daughter that was not found in unaffected family members"
    explanation: >-
      Supports FZD2 molecular testing for the autosomal dominant form of omodysplasia.
progression:
- subtype: OMOD1
  notes: >-
    Skeletal changes in recessive omodysplasia are regressive with age. The
    humerofemoral abnormalities, including distal tapering and club-like
    morphology, improve over time, and the growth plate compensatory
    hyperplasia of chondrocytes suggests partial adaptive mechanisms.
  evidence:
  - reference: PMID:14566439
    reference_title: "Recessive omodysplasia: five new cases and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the regressive nature of the humerofemoral changes
    explanation: >-
      Clinical review documents that the characteristic long bone abnormalities
      improve with age in recessive omodysplasia.
  - reference: PMID:9508243
    reference_title: "Autosomal-recessive omodysplasia: prenatal diagnosis and histomorphometric assessment of the physeal plates of the long bones."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a genetic, functional deficiency of the physeal cells, underlying the
      short-limbed dwarfism of autosomal-recessive omodysplasia, is partially
      compensated, albeit ineffectively, by an increased number of small
      chondrocytes in the proliferating zone of the physeal plate
    explanation: >-
      Histomorphometric evidence of a compensatory mechanism in the growth plate,
      with increased chondrocyte numbers partially offsetting the functional
      deficiency.
- subtype: OMOD2
  notes: >-
    In dominant omodysplasia, the skeletal phenotype is persistent into
    adulthood. Long-term observation shows humeri and femora become less
    undermodeled with age, but may develop mild bowing. Mild lower extremity
    rhizomelia may become apparent over time.
  evidence:
  - reference: PMID:29383834
    reference_title: "Nonsense mutations in FZD2 cause autosomal-dominant omodysplasia: Robinow syndrome-like phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The abnormal skeletal pattern was persistent in adolescence; however, the
      humeri and femora became less undermodeled, while the humeri and radii
      became mildly bowed
    explanation: >-
      Long-term radiological follow-up from infancy to adolescence documents
      persistence but evolution of the skeletal phenotype.
  - reference: PMID:24458798
    reference_title: "Long-term observation of a patient with dominant omodysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mild rhizomelic shortening of the lower extremities has not been
      previously reported
    explanation: >-
      Long-term follow-up reveals mild lower extremity involvement in dominant
      omodysplasia that was not apparent in earlier descriptions.
treatments:
- name: Orthopedic surgical management
  description: >
    Surgical intervention for management of radial head dislocation and other
    skeletal deformities. Limb-lengthening procedures may be considered in severe
    cases.
  treatment_term:
    preferred_term: Orthopedic surgical management
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Physical therapy
  description: >
    Rehabilitation to maintain and improve joint range of motion, particularly
    at the elbows and knees where restricted extension is common.
  treatment_term:
    preferred_term: Physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
- name: Genetic counseling
  description: >
    Genetic counseling for families, particularly to distinguish between the
    autosomal recessive and autosomal dominant forms and to inform recurrence
    risk assessment.
  treatment_term:
    preferred_term: Genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
notes: >
  The nosological distinction between autosomal recessive and autosomal dominant
  omodysplasia reflects different genetic etiologies (GPC6 vs FZD2) converging on
  related signaling pathways (Hedgehog vs Wnt) that regulate endochondral
  ossification. The phenotypic overlap with autosomal dominant Robinow syndrome
  (also caused by WNT pathway mutations) raises questions about whether OMOD2
  and AD Robinow syndrome represent a clinical continuum. Congenital heart
  defects (atrial septal defect, patent ductus arteriosus) have been reported in
  a minority of OMOD1 cases in the literature, but this is not consistently
  documented in available abstracts and requires further primary source
  verification.
📚

References & Deep Research

Deep Research

2
Asta
Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Omodysplasia. Core disease mechanisms, molecular and cellular pathways, in...
Asta Scientific Corpus Retrieval 20 citations 2026-04-02T22:41:46.471470

Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Omodysplasia. Core disease mechanisms, molecular and cellular pathways, in...

This report is retrieval-only and is generated directly from Asta results.

  • Papers retrieved: 20
  • Snippets retrieved: 20

Relevant Papers

[1] New therapeutic targets in rare genetic skeletal diseases

  • Authors: M. Briggs, Peter A. Bell, M. Wright, K. A. Pirog
  • Year: 2015
  • Venue: Expert Opinion on Orphan Drugs
  • URL: https://www.semanticscholar.org/paper/1363107f71ae6d2d60abca471cddf3da5d13644b
  • DOI: 10.1517/21678707.2015.1083853
  • PMID: 26635999
  • PMCID: 4643203
  • Citations: 37
  • Influential citations: 1
  • Summary: An overview of disease mechanisms that are shared amongst groups of different GSDs and potential therapeutic approaches that are under investigation are described to generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.
  • Evidence snippets:
  • Snippet 1 (score: 0.442) > proteins of the cartilage ECM such as type II collagen [50]. However, emerging knowledge suggests that the primary genetic defect may be less important than the cells' response to the expression of the mutant gene product [107]. Moreover, the largely overlooked response of a cell (i.e. chondrocyte) to the abnormal extracellular environment is also important for disease progression as illustrated by several GSDs discussed in this review. > It is important that 'omics'-based approaches and technologies are systematically applied to the study of rare GSDs so that definitive reference profiles and disease signatures are generated for each phenotype. These can then be used in a Systems Biology approach to identify both common and dissimilar pathological signatures and disease mechanisms. This approach is entirely dependent upon relevant in vitro and in vivo models (and also novel 'disease-mechanism phenocopies' [107]) for testing new diagnostic and prognostic tools and for determining the molecular mechanisms that underpin the pathophysiology so that effective therapeutic treatments can be developed and validated. This approach will eventually lead to personalized treatments and care strategies centred on shared disease mechanisms with the use of relevant biomarkers to monitor the efficacy of treatment and disease progression. > It is vital that all relevant stakeholders are involved from the outset in defining the appropriate outcomes of any potential therapeutic regime. The perceptions of a successful therapy can differ widely between the clinical academic community and the relevant patient-support groups and it is vital that there is engagement on all these issues. > In summary, the identification of causative genes and mutations for GSDs over the last 20 years, coupled with the generation and in-depth analysis of a plethora of relevant cell and mouse models, has derived new knowledge on disease mechanisms and suggested potential therapeutic targets. The fast-evolving hypothesis that clinically disparate diseases can share common disease mechanisms is a powerful concept that will generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.

[2] Changes in Serum Proteomic Profiles at Different Stages of Pregnancy Toxemia in Goats

  • Authors: M. Uzti̇mür, C. N. Ünal, Gurler Akpinar
  • Year: 2025
  • Venue: Journal of Veterinary Internal Medicine
  • URL: https://www.semanticscholar.org/paper/4b9c488b5dbd65d7b26fd2ad9aed70e8c4b59942
  • DOI: 10.1111/jvim.70139
  • PMID: 40492724
  • PMCID: 12150350
  • Summary: Understanding the serum proteome profiles of goats with pregnancy toxemia might help identify the proteomes and pathways responsible for the development of this disease and improve diagnosis and treatment.
  • Evidence snippets:
  • Snippet 1 (score: 0.417) > The pathophysiology and progression of this disease are not fully understood. > Traditional biomedical research has focused on the analysis of single genes, proteins, metabolites, or metabolic pathways in diseases. This molecular reductionist approach is based on the assumption that identifying genetic variations and molecular components will lead to new treatments for diseases [13][14][15][16]. However, many diseases are complex and multifactorial, and in order to determine the phenotype of such diseases, it is necessary to understand the changes that occur in more than one gene, pathway, protein, or metabolite at the cellular, tissue, and organismal levels [17][18][19]. Therefore, in recent years, proteomics, as one field of multi-omics technologies, has helped in evaluating the complex pathogenetic mechanisms of different diseases from a broad perspective and has made substantial contributions [20,21]. In veterinary medicine, proteomic analysis of metabolic diseases such as ketosis [16], hypocalcemia [22], and fatty liver [23] in dairy cows has contributed valuable insights for the definition of new pathophysiological pathways and new diagnosis and treatment protocols for these diseases. The proteomic approach can contribute importantly to a broad and detailed understanding of the changes that occur at the organismal level associated with the increase in BHBA concentration in goats with pregnancy toxemia. Our aim was to evaluate the serum protein profiles of goats with SPT or CPT using proteomic techniques to determine the proteomic profiles of these animals and to identify the relevant pathophysiological mechanisms.

[3] 18O-assisted dynamic metabolomics for individualized diagnostics and treatment of human diseases

  • Authors: E. Nemutlu, Song Zhang, N. Juranic, A. Terzic, S. Macura et al.
  • Year: 2012
  • Venue: Croatian Medical Journal
  • URL: https://www.semanticscholar.org/paper/880f053c7f060db4b990e447d0a22c4b69372ddb
  • DOI: 10.3325/cmj.2012.53.529
  • PMID: 23275318
  • PMCID: 3541579
  • Citations: 28
  • Summary: The potential use of dynamic phosphometabolomic platform for disease diagnostics currently under development at Mayo Clinic is described and discussed briefly.
  • Evidence snippets:
  • Snippet 1 (score: 0.417) > Living cells represent an integrated and interacting network of genes, transcripts, proteins, small signaling molecules, and metabolites that define cellular phenotype and function. Traditionally the focus of biomedical research was on individual genes, single protein targets, single metabolites, and metabolic or signaling pathways. This "molecular reductionist" paradigm was based on the assumption that identifying genetic variations and molecular components would lead to discovery of cures for human diseases. However, most of diseases are complex and multi-factorial and the disease phenotype is determined by the alterations of multiple genes, pathways, proteins and metabolites (at cellular, tissue, and organismal levels). Therefore, an integrated "omics" approach is more viable direction for uncovering alterations in metabolic networks, disease mechanisms, and mechanisms of drug effects. > Recent advent of large-scale metabolomics and fluxomic (metabolite dynamics and metabolic flux analysis) completed the "omics revolution" (Figure 1), where genomics, transcriptomics, proteomics, metabolomics, and fluxomics all together complement phenotype determination of living organism. Such integrated "omics" cascades provide a framework for advances in system and network biology, integrative physiology, and system medicine as well as system pharmacology and regenerative medicine. Noteworthy is the "reverse omic" approach or "metabolomicsinformed pharmacogenomics, " where discovery of specific metabolite changes have led to discovery of genetic alterations (2). Therefore, bringing new "omics" technologies to clinical practice will improve disease diagnostics and treatment by targeting drugs and procedures for each unique transcriptomic and metabolomic profiles.

[4] Organoids in gastrointestinal diseases: from bench to clinic

  • Authors: Qinying Wang, Fanying Guo, Qinyuan Zhang, Tingting Hu, Yutao Jin et al.
  • Year: 2024
  • Venue: MedComm
  • URL: https://www.semanticscholar.org/paper/9b8880d8b9d45670da950197d7e353794f51d09e
  • DOI: 10.1002/mco2.574
  • PMID: 38948115
  • PMCID: 11214594
  • Citations: 12
  • Summary: A comprehensive and systematical depiction of organoids models is drawn, providing a novel insight into the utilization of organoids models from bench to clinic and clinical adhibition.
  • Evidence snippets:
  • Snippet 1 (score: 0.402) > Organoids models offer a robust platform for investigating the potential mechanisms of GI diseases and evaluating potential therapeutic interventions.By culturing organoids derived from patients' tissues or stem cells, researchers can delve into disease-specific cellular and molecular pathways, encompassing aberrant cell signaling, perturbed immune responses, and dysfunctional metabolic processes.These disease-specific phenotypes enable the study of disease progression, screening of prospective therapeutics, as well as identification of novel drug targets and mechanisms of action for GI diseases in a clinically relevant context.

[5] Mitochondrial Dysfunction in Diabetes: Shedding Light on a Widespread Oversight

  • Authors: F. Iheagwam, A. J. Joseph, E. D. Adedoyin, Olawumi Toyin Iheagwam, Samuel Akpoyowvare Ejoh
  • Year: 2025
  • Venue: Pathophysiology
  • URL: https://www.semanticscholar.org/paper/dbf8042761c1a5fc50f8cd894cc498505abac7cb
  • DOI: 10.3390/pathophysiology32010009
  • PMID: 39982365
  • PMCID: 12077258
  • Citations: 23
  • Summary: This review aims to elucidate the complex link between mitochondrial dysfunction and diabetes, covering the spectrum of diabetes types, the role of mitochondria in insulin resistance, highlighting pathophysiological mechanisms, mitochondrial DNA damage, and altered mitochondrial biogenesis and dynamics.
  • Evidence snippets:
  • Snippet 1 (score: 0.400) > The landscape of DM research is continuously evolving, with emerging technologies and approaches offering new insights into the pathophysiology of the disease and potential therapeutic targets. Advancements in omics technologies, encompassing genomes, transcriptomics, proteomics, and metabolomics, have transformed the molecular mechanisms underlying DM [134]. High-throughput sequencing techniques enable comprehensive analysis of genetic variants, gene expression profiles, protein abundance, and metabolite levels associated with DM and its complications [135]. Single-cell omics approaches provide unprecedented resolution and granularity, allowing researchers to dissect cellular heterogeneity and identify novel cell types, subpopulations, and signalling pathways involved in DM pathogenesis. Integrating multi-omics data sets offers a systems-level perspective of DM, unravelling complex networks of molecular interactions and regulatory circuits underlying disease progression [136]. > In addition to omics technologies, advances in imaging modalities, such as MRI, PET, and optical imaging, enable non-invasive visualisation and quantification of metabolic, functional, and structural changes. Molecular imaging probes targeting specific biomarkers and metabolic pathways provide valuable insights into disease mechanisms and treatment responses in preclinical and clinical settings [85]. Despite significant progress in DM research, numerous unanswered questions and knowledge gaps persist, hindering the ability to develop effective prevention and treatment strategies. Key areas requiring further investigation include the role of epigenetics, environmental factors, and the microbiome in DM susceptibility and progression. Moreover, the interaction between environmental cues and genetic predisposition remains incompletely understood, highlighting the need for comprehensive multi-omics studies and large-scale epidemiological analyses to identify gene-environment interactions and modifiable risk factors for DM [137]. Furthermore, the heterogeneity of DM phenotypes and clinical outcomes poses a challenge for personalised medicine approaches, necessitating robust biomarkers and predictive models to stratify patients based on disease subtypes, prognosis, and treatment response [138].

[6] From molecular signatures to predictive biomarkers: modeling disease pathophysiology and drug mechanism of action

  • Authors: A. Heinzel, P. Perco, G. Mayer, R. Oberbauer, A. Lukas et al.
  • Year: 2014
  • Venue: Frontiers in Cell and Developmental Biology
  • URL: https://www.semanticscholar.org/paper/36d6c03a528c1358c0ae5b667cca5ce73b2fbee5
  • DOI: 10.3389/fcell.2014.00037
  • PMID: 25364744
  • PMCID: 4207010
  • Citations: 23
  • Summary: This work exemplifies a computational workflow for expanding from statistics-based association analysis toward deriving molecular pathway and process models for characterizing phenotypes and drug mechanism of action, in turn providing precision medicine hypotheses utilizing predictive biomarkers.
  • Evidence snippets:
  • Snippet 1 (score: 0.396) > In such scenario a biomarker needs to serve as proxy of key mechanistic factors characterizing and driving a disease on a patient-specific level, combined with educating on the specific interference of disease mechanism with drug mechanism of action. For capturing these constraints a detailed molecular map of a clinical phenotype and its interference with a drug mechanism of action is needed, and here integration of Omics profiling adds to identifying such mechanisms (Fechete et al., 2011;Mühlberger et al., 2012). > An a priori stratification of patients based on an appropriately chosen biomarker panel reflecting the pathophysiology of a given patient (group) allowing to determine a match with a specific drug's mechanism of action appears as promising approach. As recently discussed by Himmelfarb et al. fresh approaches are critical in finding therapies to kidney disease benefiting patients, outlining the importance of improving the translational aspect in clinical research (Himmelfarb and Tuttle, 2013). Here, omics technologies have added significantly to the data landscape characterizing chronic kidney disease, however, in a first instance mainly expanding the candidate set of apparently relevant processes and pathways, going in hand with a large number of biomarker candidates, which individually hamper clinically relevant assessment on disease progression (Fechete et al., 2011;Hellemons et al., 2012). > Integrative approaches in the realm of Systems Biology have been proposed for reaching a consensus description of chronic kidney disease pathophysiology, including molecular models of DN as well as of the reno-cardial axis (He et al., 2012;Komorowsky et al., 2012;Mayer et al., 2012;Heinzel et al., 2013). Still, a translation process needs to be followed, joining disease pathophysiology, stratification markers allowing enrichment strategies, combined with on a molecular mechanistic level matching drugs for allowing precision medicine (Mirnezami et al., 2012). In this work we exemplify such procedure on DN being the major clinical presentation leading to end stage renal disease.

[7] Role of Transcriptomics in Precision Oncology

  • Authors: Ruby Srivastava
  • Year: 2024
  • Venue: Reports of Radiotherapy and Oncology
  • URL: https://www.semanticscholar.org/paper/0bd862558bbb7286336111d9dfd232b5f905d3d9
  • DOI: 10.5812/rro-142195
  • Citations: 4
  • Summary: : Transcriptome profiling is one of the most widely used approaches in the field of multiomics research. It plays a crucial role in the prognostic, diagnostic, and predictive treatment of cancer patients. Novel next-generation sequencing (NGS) technologies permit the identification of cancer biomarkers, gene signatures, and their abnormal expression, affecting oncogenic and molecular targets and novel biomarkers for cancer therapies. Multiomics studies have changed the overall understanding o...
  • Evidence snippets:
  • Snippet 1 (score: 0.395) > : Transcriptome profiling is one of the most widely used approaches in the field of multiomics research. It plays a crucial role in the prognostic, diagnostic, and predictive treatment of cancer patients. Novel next-generation sequencing (NGS) technologies permit the identification of cancer biomarkers, gene signatures, and their abnormal expression, affecting oncogenic and molecular targets and novel biomarkers for cancer therapies. Multiomics studies have changed the overall understanding of cancer and opened a precise perspective for tumor diagnostics and therapy. The use of these approaches has strengthened our understanding of disease pathophysiology and classifications at the molecular level, including specific interference with drug mechanisms of action. Still, it has limited added value in the clinical setting. The omics data on precision medicine include the application of data from genes, transcripts, and proteins for diagnosis, monitoring of diseases, risk factor determination, counseling, and development of novel therapeutics. Bioinformatics applications have expanded statistics-based analysis toward deriving molecular pathways and process models for characterizing phenotypes and drug action mechanisms. In this review, we will discuss transcriptomics and interference analysis that allows the identification of predictive biomarkers at the molecular level to test drug response and analyze the molecular process interface of disease progression-relevant pathophysiology and mechanism of action to propose predictive biomarkers.

[8] Investigating the Transition of Pre-Symptomatic to Symptomatic Huntington’s Disease Status Based on Omics Data

  • Authors: Christiana C. Christodoulou, M. Zachariou, Marios Tomazou, E. Karatzas, C. Demetriou et al.
  • Year: 2020
  • Venue: International Journal of Molecular Sciences
  • URL: https://www.semanticscholar.org/paper/04a48e68a0a0ad9eca22aeffdb8c22c7fb41ed86
  • DOI: 10.3390/ijms21197414
  • PMID: 33049985
  • PMCID: 7582902
  • Citations: 26
  • Influential citations: 2
  • Summary: The genes, pathways and metabolites identified for each HD stage can provide a better understanding of the mechanisms that become altered in each disease stage, leading to an improvement in clinical symptoms and hopefully a delay in the age of onset.
  • Evidence snippets:
  • Snippet 1 (score: 0.387) > HD is a monogenetic and incurable disease and at the same time its molecular manifestations remain highly complex and involve multiple cellular processes, genes, and metabolites, which needs to be investigated to understand HD pathology. Systems bioinformatics (SB) allows the integration of different biological omics data to better understand the biological pathways, mechanisms, genes and metabolites involved in HD and lead to possible therapeutic treatments and biomarker discovery. > SB is an interdisciplinary field which combines the research fields of systems biology and bioinformatics. SB allows the integration of biological data across the omics categories such a genomics, transcriptomics, proteomics, metabolomics, lipidomics, epigenomics and several types of omics data [7]. > A major approach in this direction is the generation and construction of biological networks representing each level of omics data and their integration in a layered network that permits the exchange of information between and within the layers. The goal is to reveal synergistic relationships among numerous factors rather than explore each entity individually. This data integration approach results in the construction of highly complex molecular interaction networks. The biological data, obtained through large-scale omics analysis can provide a better understanding into biological mechanisms and pathways and how a dysfunction in these mechanisms and pathways can cause the disease [7]. Furthermore, the emerging importance of biological network-based approaches, allows for potential biological and clinical applications by suggesting an intuitive and trustworthy approach to explore the biological and molecular complexity of a disease of interest [8]. > The metabolome is defined as the complete set of small chemical molecules found within a biological samples (urine, cerebrospinal fluid (CSF), serum, plasma), tissues and cells. Changes and interactions in gene and protein expression and the environment are directly revealed in the metabolome making it more chemically and physically complex than the genome, transcriptome and proteome. Metabolites are affected by the upstream influence of the genome, proteome, environmental and lifestyle factors, as well as medication and underlying diseases [9]. > Metabolomics is an omics category focused in the study of metabolites. Metabolites are defined as small biological and low molecular weight (<1500 Da) compounds, they are the end-products of metabolism [10].

[9] Renal ciliopathies: promising drug targets and prospects for clinical trials

  • Authors: L. Devlin, Praveen Dhondurao Sudhindar, J. Sayer
  • Year: 2023
  • Venue: Expert Opinion on Therapeutic Targets
  • URL: https://www.semanticscholar.org/paper/ab2155b6e12caba53d57ac0e8ce28860d69ec9fd
  • DOI: 10.1080/14728222.2023.2218616
  • PMID: 37243567
  • Citations: 10
  • Summary: The advances in basic science and clinical research into renal ciliopathies which have yielded promising small compounds and drug targets are reviewed, within both preclinical studies and clinical trials.
  • Evidence snippets:
  • Snippet 1 (score: 0.387) > Although renal ciliopathies can be classified into distinct syndromes, causative mutations in genes encoding proteins involved in the primary cilium or centrosome mean they may share overlapping mechanisms of disease, which may be amenable for therapeutic intervention (Figure 2). Abnormal functioning of proteins involved in ciliogenesis, such as CEP164, can prevent proper cilia formation, which will effect a myriad of downstream ciliary signaling pathways. Additionally, mutations in genes encoding for proteins involved in cargo trafficking or regulation, such as CEP290, will have implications for signal pathway transduction, as well as mutations in components of signaling pathways themselves, such as PKD1. In regard to renal ciliopathies, abnormalities in signaling pathways such as cAMP, Shh, Wnt, mTOR, and AMPK, likely cause misoriented cellular divisions, increased proliferation, increased fluid secretion and subsequent cystogenesis, consequently leading to further kidney damage. Ciliary and centriolar proteins which have roles in DDR and cell cycle regulation may also be driving a renal cystogenesis phenotype alongside increased fibrosis and apoptosis. Increased inflammation and dysfunctional mitochondria are also byproducts of dysregulated signaling pathways have been shown to contribute to the progression of renal ciliopathies. Extensive reviews of mechanisms of renal ciliopathy diseases have recently been performed [23,24]. Importantly, due to the wide range of cellular processes that primary cilia regulate, it is likely that in each syndrome there are multiple pathogenic drivers of disease. In some ways, this is advantageous as it offers many points for potential therapeutic targets. However, the cross talk between pathways and feedback loops introduces complications of changing one pathway without negatively affecting another. Further challenges arise with core biological pathways, such as Shh signaling, in which modification in vitro may be beneficial, but systemic treatment is unrealistic due to the expected severe side effects [18,24,116].

[10] Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes.

  • Authors: S. Mulder, P. Perco, C. Oxlund, Uzma F Mehdi, T. Hankemeier et al.
  • Year: 2020
  • Venue: Translational research : the journal of laboratory and clinical medicine
  • URL: https://www.semanticscholar.org/paper/e5f7ffaa67fba1fe09d82c2d3787ad398d175bb6
  • DOI: 10.1016/j.trsl.2020.04.010
  • PMID: 32438071
  • Citations: 9
  • Summary: The data suggest that urinary metabolites may be used as a tool to tailor optimal therapy and move in the direction of personalized medicine.
  • Evidence snippets:
  • Snippet 1 (score: 0.386) > In-silico modeling of spironolactone mechanism of action and DKD pathophysiology. Network-based molecular models reflecting spironolactone mechanism of action as well as DKD pathophysiology were generated following previously described and successfully applied computational workflows. 8,9 In brief, molecular features associated with spironolactone were consolidated from 3 data sources, namely scientific literature, DrugBank, and a transcriptomics data set from DrugMatrix. Molecular features were defined as genes, transcripts, or proteins. Scientific articles annotated with spironolactone as major MeSH term were retrieved and genes were extracted using NCBI's gene2pubmed file. This set of genes was complemented by drug targets listed in DrugBank for spironolactone. 10 We further extracted transcripts being differentially expressed between spironolactone-treated and untreated kidney samples of animal models as stored in DrugMatrix. 11 The unique set of spironolactone associated molecular features was mapped onto a hybrid interaction network including protein-protein interaction data from IntAct, BioGrid, and Reactome together with computationally inferred relations. 12 Interactions between members of the spironolactone feature set were extracted and the MCODE algorithm was used to identify clusters of highly interconnected proteins. 13 A previously published DKD molecular model was used which was constructed following the same logic using data from scientific literature as well as from Omics datasets in the context of DKD. 7 Proteomics data of the published CKD273 proteomics classifier were used in order to identify DKD processes linked with DKD progression by mapping the set of proteins in the CKD273 classifier onto the DKD molecular network thus defining progression-associated process units. 14 Network interference analysis and identification of candidate metabolites. Network alignment method was used to identify DKD molecular processes linked to DKD prognosis affected by spironolactone treatment on the molecular level. Metabolites linked to proteins in affected DKD molecular processes were identified via enzyme-metabolite associations as stored in the Human Metabolome Database and forwarded to measurements in clinical samples. 15 A

[11] Computational drug discovery approaches identify mebendazole as a candidate treatment for autosomal dominant polycystic kidney disease

  • Authors: P. Brownjohn, A. Zoufir, Daniel J O’Donovan, Saatviga Sudhahar, A. Syme et al.
  • Year: 2024
  • Venue: Frontiers in Pharmacology
  • URL: https://www.semanticscholar.org/paper/a595e78572ca02b8cb2897bfc4a989a2b021b279
  • DOI: 10.3389/fphar.2024.1397864
  • PMID: 38846086
  • PMCID: 11154008
  • Citations: 2
  • Summary: It is determined that the anthelmintic mebendazole was a potent anti-cystic agent in human cellular and in vivo models of ADPKD, and is likely acting through the inhibition of microtubule polymerisation and protein kinase activity.
  • Evidence snippets:
  • Snippet 1 (score: 0.385) > Targets and molecules were ultimately filtered for validation based on biological and chemical insights, and the potential for clinical translation.Earlier this year, Wilk et al., 2023 applied a similar transcriptomic approach to us, in that case making use of publicly available transcriptomic datasets to create Pkd2-specific ADPKD disease signatures, from which signature reversion was sought from the Library of Integrated Network-based Cellular Signatures (LINCs) drug signature database in order to identify drug repurposing candidates.While one group has previously made use of a knowledge graph-based approach to prioritise preclinically active compounds with the highest chance of clinical translation (Malas et al., 2019), to our knowledge, the current study provides the first combined application of transcriptomic and machine-learning approaches to identify and prioritise putative treatments for ADPKD, and further deconvolute potential mechanisms of action for experimental validation. > In summary we report, using computational, in vitro and in vivo approaches, that the anthelmintic drug mebendazole ameliorates disease-relevant phenotypes in cellular and animal models of ADPKD.We further show that this effect is likely primarily due to the inhibitory effect of mebendazole on the polymerisation of microtubules, which underlie cellular processes important in ADPKD, including cell proliferation, transport, and cilia signalling, and extends previous work linking the importance of the microtubule network to ADPKD pathophysiology.We also describe the inhibitory profile of mebendazole on known and novel protein kinase targets, some of which have previously been implicated in ADPKD, suggesting mebendazole may be acting via polypharmacology to impact disease mechanisms.We acknowledge that further experimental efforts will be required to confirm the actions of mebendazole on these putative targets in relevant disease model systems.It would be particularly informative to investigate these mechanisms in dedicated in vivo studies, where the effects of mebendazole on a wider range of ADPKD-relevant cell types and phenotypes could be evaluated.

[12] Cellular reprogramming and inherited peripheral neuropathies: perspectives and challenges

  • Authors: M. Saporta
  • Year: 2015
  • Venue: Neural Regeneration Research
  • URL: https://www.semanticscholar.org/paper/8c3dabb1b4abf93506e2026564b8a329c0ec37c6
  • DOI: 10.4103/1673-5374.158345
  • PMID: 26199602
  • PMCID: 4498347
  • Citations: 4
  • Summary: iPSC-based models of neuromuscular disorders, including amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA) and inherited peripheral neuropathies, have successfully reproduced pathophysiological findings from previous animal and cellular models and have also identified new disease mechanisms with potential therapeutical implications.
  • Evidence snippets:
  • Snippet 1 (score: 0.384) > Inherited peripheral neuropathies (or Charcot-Marie-Tooth disease, CMT) are a phenotypically and genetically heterogeneous group of disorders, which are currently untreatable. They are the most common inherited neuromuscular disorder, affecting around 1 in every 2,500 people (over 120,000 people in the US). Based on clinical neurophysiological and histopathological features, inherited neuropathies can be divided into two major forms: demyelinating (type 1) and axonal (type 2) CMT (Saporta, 2014). From a biological standpoint, these two major forms of CMT are associated with mutations in different sets of genes, affecting Schwann cell development and myelination (type 1) or peripheral axon physiology (type 2), although some overlap does exist (Figure 1). To date, over 70 genes have been associated with a CMT phenotype, making CMT an attractive natural model to study peripheral nervous system biology. Despite significant advances made in our knowledge of disease mechanisms in CMT, findings from animal models have so far translated poorly in clinical trials, underscoring the need for innovative methods to investigate the pathophysiology of these human disorders. Induced pluripotent stem cells (iPSCs) offer an unlimited source of patient specific, disease-relevant cell lines that can be used as a platform for identification of disease mechanisms, discovery of molecular targets and development of phenotypic screens for drug discovery (Saporta et al., 2011). iPSC-based models of neuromuscular disorders, including amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA) and inherited peripheral neuropathies, have successfully reproduced pathophysiological findings from previous animal and cellular models and have also identified new disease mechanisms with potential therapeutical implications.

[13] Human Dermal Fibroblast: A Promising Cellular Model to Study Biological Mechanisms of Major Depression and Antidepressant Drug Response

  • Authors: P. Mesdom, R. Colle, É. Lebigot, S. Trabado, Eric Deflesselle et al.
  • Year: 2020
  • Venue: Current Neuropharmacology
  • URL: https://www.semanticscholar.org/paper/79368e365458486de96794333613c12a6063bf54
  • DOI: 10.2174/1570159X17666191021141057
  • PMID: 31631822
  • PMCID: 7327943
  • Citations: 12
  • Summary: This review highlights the great and still underused potential of HDF, which stands out as a very promising tool in the understanding of MDD and AD mechanisms of action.
  • Evidence snippets:
  • Snippet 1 (score: 0.381) > Background: Human dermal fibroblasts (HDF) can be used as a cellular model relatively easily and without genetic engineering. Therefore, HDF represent an interesting tool to study several human diseases including psychiatric disorders. Despite major depressive disorder (MDD) being the second cause of disability in the world, the efficacy of antidepressant drug (AD) treatment is not sufficient and the underlying mechanisms of MDD and the mechanisms of action of AD are poorly understood. Objective The aim of this review is to highlight the potential of HDF in the study of cellular mechanisms involved in MDD pathophysiology and in the action of AD response. Methods The first part is a systematic review following PRISMA guidelines on the use of HDF in MDD research. The second part reports the mechanisms and molecules both present in HDF and relevant regarding MDD pathophysiology and AD mechanisms of action. Results HDFs from MDD patients have been investigated in a relatively small number of works and most of them focused on the adrenergic pathway and metabolism-related gene expression as compared to HDF from healthy controls. The second part listed an important number of papers demonstrating the presence of many molecular processes in HDF, involved in MDD and AD mechanisms of action. Conclusion The imbalance in the number of papers between the two parts highlights the great and still underused potential of HDF, which stands out as a very promising tool in our understanding of MDD and AD mechanisms of action

[14] Clinical metabolomics in type 2 diabetes mellitus: from pathogenesis to biomarkers

  • Authors: Chuanxin Liu, Hetao Chen, Yujin Ma, Lei Zhang, Lulu Chen et al.
  • Year: 2025
  • Venue: Frontiers in Endocrinology
  • URL: https://www.semanticscholar.org/paper/36f8d26a208b7b96763df2e9aa3211e440031c0e
  • DOI: 10.3389/fendo.2025.1501305
  • PMID: 40070584
  • PMCID: 11893406
  • Citations: 10
  • Summary: The results facilitate understanding the pathophysiology and mechanism of type 2 diabetes mellitus and supports research in accurate diagnosis, risk prediction, curative effect, distinct stages, and prognosis judgment of T2DM.
  • Evidence snippets:
  • Snippet 1 (score: 0.381) > T2DM is a chronic disease characterized by two primary pathophysiological mechanisms: ① a reduction in the mass and function of pancreatic b cells, ranging from 20% to 65%, which leads to impaired insulin secretion; ② insulin resistance, where cells in muscles, fat, and liver tissues fail to respond adequately to insulin (9). Consequently, higher levels of insulin are required to maintain normal blood glucose concentrations by inhibiting hepatic glucose production and promoting glucose uptake in muscle and adipose tissues. Prolonged exposure to elevated levels of circulating insulin leads to the development of insulin resistance in peripheral tissues, and over time, the pancreas fails to produce sufficient insulin to overcome this cellular resistance (10). However, due to the long latent period and absence of obvious symptoms initially, reversing T2DM with drug intervention is difficult after the symptoms are exposed or clinically confirmed in light of clear diagnostic criteria. According to the literature, the pathogenesis and process of metabolic syndromes such as diabetes and its complications are mainly reflected in the metabolite network, and the mechanism changes at the gene level are also found in the network. Studies have shown that some related metabolites in patients with diabetes have changed before the occurrence of obvious organic damage (11). Therefore, it is necessary to scientifically prevent T2DM in the early stages of disease onset. Fortunately, clinical metabolomics were employed to understand the progression pathologies of T2DM and its corresponding complications in detail (12). Studies have demonstrated that metabolomic analysis enables the exploration of metabolic disorders associated with T2DM, thereby deepening our understanding of disease progression (13,14). This approach has the potential to facilitate novel clinical diagnoses and the development of effective treatment strategies. Moreover, identifying specific metabolites may provide promising biomarkers for the early prediction, prevention, and management of hyperglycemia and its complications (15). In recent years, excellent progress has been made in the study of T2DM and its complications through High throughput sequencing method, i.e., a discipline specifically focused on metabolic small molecules. > Clinical metabolomics is a type of systems biology research closely linked to phenotype.

[15] Focus on Achalasia in the Omics Era

  • Authors: Anna Laura Pia Di Brina, O. Palmieri, Anna Lucia Cannarozzi, F. Tavano, Maria Guerra et al.
  • Year: 2024
  • Venue: International Journal of Molecular Sciences
  • URL: https://www.semanticscholar.org/paper/650bd88078a05683426d4e086abaa2c68729b07d
  • DOI: 10.3390/ijms251810148
  • PMID: 39337632
  • PMCID: 11431880
  • Citations: 2
  • Summary: This narrative review of the scientific literature is aimed to provide a comprehensive assessment of the state-of-the-art knowledge on omics of achalasia, with particular attention to those considered relevant to the pathogenesis of the disease.
  • Evidence snippets:
  • Snippet 1 (score: 0.380) > Basically all diseases, and not just so-called "complex diseases", are multifaceted because countless interconnected biological components contribute to their pathophysiology [8]. Any pathology has an intricate mix of genetic, epigenetic, environmental and behavioral factors that determine their onset and progression. Consequently, it is evident that studying each component of the disease in isolation, although it gives valuable information on any markers or sheds light on the different biological pathways between patients with a disease and a control group, is not sufficient to understand the intricate biological mechanisms at play [9]. For example, analysis of a single gene can reveal mutations associated with a disease, but cannot explain the entire clinical picture without considering the interaction of that gene with other genes, proteins and metabolites within the biological network. > So the need to study all components in a much more comprehensive way has emerged, hence the emphasis on omes and omics, defined, respectively, as the object of study of such field and its analysis. Substantially, omics is intended to improve our understanding of human biology and promote health and well-being through biomedical science and research [10]. Examples of omics disciplines include the identification of genes (genomics), messenger RNA (transcriptomics), epigenetic factors (epigenomics), proteins (proteomics) and finally, metabolites (metabolomics). > Thus ideally, different technologies would be combined to help diagnose disease and to generate effective clinically actionable tools to aid medical decision-making, generating a holistic picture of human phenotypes and disease. Furthermore, the integration of various types of omics data, multi-omics and clinical data, enables the production of more detailed information and is commonly used to discover potential underlying changes that trigger diseases contributing to the understanding of the pathogenic mechanisms or to identify potential targets for treatments. Indeed, it is expected that omics data will help the development of new and effective drugs, aimed at identifying biomarkers, novel molecular or protein targets for disease-modifying therapies useful for early diagnosis, disease staging and prediction progression. The National Cancer Institute defined biomarkers as biological molecules in blood, bodily fluids, or tissues that reveal whether a process, condition, or disease is normal or aberrant.

[16] Molecular Mechanisms and Risk Factors for the Pathogenesis of Hydrocephalus

  • Authors: Jing-wen Li, Xinjie Zhang, Jianfeng Guo, Chen Yu, Jun Yang
  • Year: 2022
  • Venue: Frontiers in Genetics
  • URL: https://www.semanticscholar.org/paper/d53bdf5f73f54a6d5a8be8777d23c465a13e9185
  • DOI: 10.3389/fgene.2021.777926
  • PMID: 35047005
  • PMCID: 8762052
  • Citations: 15
  • Influential citations: 2
  • Summary: Some possible fundamental molecular mechanisms and facilitating risk factors involved in the pathogenesis of hydrocephalus are elicited, and knowledge could be used to improve patient care in different ways, such as early precise diagnosis and effective therapeutic regimens.
  • Evidence snippets:
  • Snippet 1 (score: 0.379) > Cwh43 modifies the glycosylphosphatidylinositol-anchored proteins on the ependymal cells, and the mutant Cwh43 is related to iNPH in both humans and mice. The clinical features manifest as late-onset communicating hydrocephalus with symptoms of gait and balance dysfunction (Yang et al., 2021a). > The clinical manifestation and progression, as well as experimental investigations, indicate that hydrocephalus is a complex disease with polygenic involvement, rather than a simple CSF accumulation disorder. Although the current studies have revealed that some genetic mutations are involved in the pathogenesis of hydrocephalus, how these mutations are associated with the disorder of CSF circulation and their pathogenic roles in the pathological progression of hydrocephalus still remain largely unknown. Previous studies indicated that a lot of genetic mutations were relevant to the disorders of ciliary and/or centrosome, resulting in the dysfunction of the glymphatic system. However, how these mutations and their interactions contribute to the pathogenesis of hydrocephalus needs to be further elucidated. Moreover, there is still a lack of basic knowledge on the mechanisms underlying the cognitive functional impairment of hydrocephalus. Therefore, further extensive studies should be conducted to explore the underlying molecular mechanisms of identified and/or unidentified genes in the pathophysiology of hydrocephalus. Based on our knowledge, we propose that the genetic mutations relevant to ciliary and centrosomal proteins and the interaction between glymphatic system and ciliary/ centrosomal structures/functions may be a critical molecular mechanism in the pathophysiology of hydrocephalus. In addition, based on these fundamental molecular mechanisms, it is noteworthy that environmental and other acquired risks or etiological factors are also involved in the facilitation of ventricular enlargement.

[17] Mitochondrial transplantation as a promising therapy for mitochondrial diseases

  • Authors: Tian-Guang Zhang, Chaoyu Miao
  • Year: 2022
  • Venue: Acta Pharmaceutica Sinica. B
  • URL: https://www.semanticscholar.org/paper/72802097939b0bffc319c93d05128d7e3160e0eb
  • DOI: 10.1016/j.apsb.2022.10.008
  • PMID: 36970208
  • PMCID: 10031255
  • Citations: 82
  • Influential citations: 1
  • Summary: Different techniques used in mitochondrial isolation and delivery, mechanisms of mitochondrial internalization and consequences of mitochondrial transplantation, along with challenges for clinical application are presented.
  • Evidence snippets:
  • Snippet 1 (score: 0.377) > Mitochondria, the vital organelles of eukaryotic cells, are integrators of various cellular metabolic pathways, including oxidative phosphorylation, fatty acid oxidation, urea cycle, Krebs cycle, ketogenesis and gluconeogenesis 1 . Mitochondria are also important in many other essential cellular processes such as calcium homeostasis, lipid metabolism, amino acid metabolism, biosynthesis of heme, and thermogenesis 2 . However, they also have important roles in many pathways which can cause both apoptosis and necrosis 3 . Therefore, the importance of the mitochondrion in the maintenance of cellular homeostasis is well established, meanwhile a large amount of evidence shows that mitochondrial dysfunction is deleterious 4 . > Due to the essential function of mitochondria in the human body, mitochondrial dysfunction causes a great variety of mitochondrial diseases, which can affect almost all the organs in the body and present at any age 4,5 . Mitochondrial diseases are a group of metabolic disorders characterized by energy metabolism dysfunction. The pathophysiology is further complicated by the involvement of genetic mutations in nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) which encode mitochondrial proteins. This means that mitochondrial diseases may result from inheritance for nDNA mutations and maternal inheritance for mtDNA mutations. The estimated minimum prevalence of mitochondrial diseases is 1 in 5000, whereas it could be higher 6 . > As advances in molecular and biochemical methodologies led to a better understanding of the mechanisms of mitochondrial disorders for various diseases, mitochondria have become a major target for research institutions and pharma companies. Pharmacological approaches include dietary supplements such as agents increasing respiratory chain function (coenzyme Q10 and riboflavin), agents inducing mitochondrial biogenesis (AICAR and bezafibrate), antioxidants (vitamin C and vitamin E), mitochondrial substrates (L-carnitine) and so on 7,8 . However, these agents fail to significantly alleviate disease symptoms or effectively slow disease progressions, there has therefore been no satisfactory therapeutic strategy available for mitochondrial diseases so far 9 . In addition, all new drugs under clinical trials for treatment of mitochondrial diseases are unable to cure these diseases permanently 9 .

[18] The ties that bind: functional clusters in limb-girdle muscular dystrophy

  • Authors: E. Barton, C. A. Pacak, Whitney L. Stoppel, P. Kang
  • Year: 2020
  • Venue: Skeletal Muscle
  • URL: https://www.semanticscholar.org/paper/653422e1a9dc9cc7f16758b10f3f203155bc68c9
  • DOI: 10.1186/s13395-020-00240-7
  • PMID: 32727611
  • PMCID: 7389686
  • Citations: 23
  • Summary: A deeper understanding of these disease pathways could yield a new generation of precision therapies that would each be expected to treat a broader range of LGMD patients than a single subtype, thus expanding the scope of the molecular medicines that may be developed for this complex array of muscular dystrophies.
  • Evidence snippets:
  • Snippet 1 (score: 0.377) > Pyridine nucleotide-disulfide reductase [55] Many of the protein functions listed require further confirmation or are disputed these methodologies. Those patients with moderate disease phenotypes regardless of the underlying causative gene mutation would likely fall into a category where there may be interest in testing a pharmacological treatment (that could be halted) but reduced interest in a more permanent experimental strategy. For all of the above-mentioned reasons, the identification of unifying therapeutic targets applicable to multiple subtypes of > LGMDs is highly desirable. > To identify such targets, we should first consider the question: What binds all of these LGMDs together? The two core phenotypic features are progressive proximal muscle weakness, along with characteristic signs of muscle fiber destruction on biopsy, referred to as "dystrophic" features. Nuances in clinical presentation have helped to distinguish some of the LGMDs, such as the frequent occurrence of difficulty walking on tiptoes in LGMD R2 (LGMD2B), caused by dysferlin deficiency. However, heterogeneity associated with variable ages of onset and ranges of severity makes it generally difficult to distinguish and diagnose LGMD subtypes based on clinical presentation alone. A change in perspective is in order to aid in understanding disease pathways responsible for clinical features even when the genetic mutation is unknown. Further, given the large number of genespecific LGMD subtypes, it could very well be that several major disease mechanisms may be shared across the family of diseases. Yet despite careful studies that have collectively determined the cellular localization of most proteins associated with LGMD (Fig. 1), there is limited knowledge of potentially unifying molecular disease mechanisms. We assert that the identification of functional clusters of these proteins, grouped by such common mechanisms, will streamline our understanding of the disease processes and identify therapeutic targets relevant to individuals in multiple disease subgroups, including individuals whose pathogenic mutations have not been found. By extension, this approach may serve as a tool to not only find common mechanisms, but may also help to distinguish LGMD subtypes that do not share similar functional patterns, and afford further refinement of potential treatments.

[19] The ties that bind: functional clusters in limb-girdle muscular dystrophy

  • Authors: E. Barton, C. A. Pacak, Whitney L. Stoppel, Peter B. Kang
  • Year: 2020
  • Venue: Skeletal Muscle
  • URL: https://www.semanticscholar.org/paper/3493c658bb8716d789a05ddf292162832e064e47
  • DOI: 10.1186/s13395-020-00240-7
  • Summary: A deeper understanding of these disease pathways could yield a new generation of precision therapies that would each be expected to treat a broader range of LGMD patients than a single subtype, thus expanding the scope of the molecular medicines that may be developed for this complex array of muscular dystrophies.
  • Evidence snippets:
  • Snippet 1 (score: 0.377) > Pyridine nucleotide-disulfide reductase [55] Many of the protein functions listed require further confirmation or are disputed these methodologies. Those patients with moderate disease phenotypes regardless of the underlying causative gene mutation would likely fall into a category where there may be interest in testing a pharmacological treatment (that could be halted) but reduced interest in a more permanent experimental strategy. For all of the above-mentioned reasons, the identification of unifying therapeutic targets applicable to multiple subtypes of > LGMDs is highly desirable. > To identify such targets, we should first consider the question: What binds all of these LGMDs together? The two core phenotypic features are progressive proximal muscle weakness, along with characteristic signs of muscle fiber destruction on biopsy, referred to as "dystrophic" features. Nuances in clinical presentation have helped to distinguish some of the LGMDs, such as the frequent occurrence of difficulty walking on tiptoes in LGMD R2 (LGMD2B), caused by dysferlin deficiency. However, heterogeneity associated with variable ages of onset and ranges of severity makes it generally difficult to distinguish and diagnose LGMD subtypes based on clinical presentation alone. A change in perspective is in order to aid in understanding disease pathways responsible for clinical features even when the genetic mutation is unknown. Further, given the large number of genespecific LGMD subtypes, it could very well be that several major disease mechanisms may be shared across the family of diseases. Yet despite careful studies that have collectively determined the cellular localization of most proteins associated with LGMD (Fig. 1), there is limited knowledge of potentially unifying molecular disease mechanisms. We assert that the identification of functional clusters of these proteins, grouped by such common mechanisms, will streamline our understanding of the disease processes and identify therapeutic targets relevant to individuals in multiple disease subgroups, including individuals whose pathogenic mutations have not been found. By extension, this approach may serve as a tool to not only find common mechanisms, but may also help to distinguish LGMD subtypes that do not share similar functional patterns, and afford further refinement of potential treatments.

[20] Nasopharyngeal Carcinoma Signaling Pathway: An Update on Molecular Biomarkers

  • Authors: W. Tulalamba, T. Janvilisri
  • Year: 2012
  • Venue: International Journal of Cell Biology
  • URL: https://www.semanticscholar.org/paper/307cb9186444d9dad6e2e3b53763be0de76de186
  • DOI: 10.1155/2012/594681
  • PMID: 22500174
  • PMCID: 3303613
  • Citations: 93
  • Influential citations: 5
  • Summary: The molecular signaling pathways in the NPC are discussed for the holistic view of NPC development and progression and the important insights toward NPC pathogenesis may offer strategies for identification of novel biomarkers for diagnosis and prognosis.
  • Evidence snippets:
  • Snippet 1 (score: 0.374) > In the pregenomic eras, highly integrated and complex circuitry of molecular signaling in NPC pathogenesis was only partially understood. Over the past decade, the knowledge of the molecular mechanisms in NPC carcinogenesis has been rapidly accumulated. Dysregulation and abnormal protein expression of molecules in certain signaling pathways involved in cellular functions including proliferation, adhesion, survival, and apoptosis has been demonstrated in the NPC cells. Detailed information on the complex network in signaling pathway leading to a coordinated pattern of gene expression and regulation in NPC will undoubtedly provide important clues to develop novel prognostic and therapeutic strategies for this cancer. Refining molecular markers into clinically relevant assays may assist in the detection of NPC in asymptomatic patients, as well as stage classification and monitoring disease progression and treatments. Furthermore, selective regulation of particular proteins targeting cancer cell proliferation, invasion, and apoptosis is a hopeful prospect for future anticancer therapy that slow disease progression and improve survival.

Notes

  • This provider combines search_papers_by_relevance with snippet_search.
  • No synthesis or second-stage model call is performed.
OpenAI
Target Disease
o3-deep-research-2025-06-26 120 citations 2026-04-02T22:48:03.938446

Target Disease

Disease Name: Omodysplasia (OMOD) – a rare genetic skeletal dysplasia affecting limb development
MONDO ID: MONDO:0009779 (Autosomal recessive form, OMOD1); MONDO:0008123 (Autosomal dominant form, OMOD2)
Category: Mendelian disorder (skeletal dysplasia)

Core Pathophysiology

Omodysplasia is characterized by profound disruptions in endochondral bone development driven by mutations in key developmental signaling pathways. In autosomal recessive Omodysplasia (OMOD1), biallelic loss-of-function mutations in GPC6 (glypican 6) impair Hedgehog signaling in growth plate cartilage (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Glypican-6 is a cell-surface heparan sulfate proteoglycan that normally augments Indian hedgehog (IHH) signaling during bone growth. Loss of GPC6 results in reduced Hedgehog pathway activity in the cartilage growth plate, leading to defective chondrocyte proliferation and impaired endochondral ossification (GO:0001958) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Consequently, long bones cannot elongate normally, causing rhizomelic (proximal) limb shortening and skeletal deformities. In the autosomal dominant form (OMOD2), heterozygous mutations in FZD2 (Frizzled-2) disrupt Wnt signaling required for limb and facial morphogenesis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Frizzled-2 is a receptor for Wnt morphogens, and pathogenic truncating mutations (e.g. p.Trp548) abolish the receptor’s intracellular Dishevelled-binding motif (pmc.ncbi.nlm.nih.gov). The mutant FZD2 cannot effectively transmit canonical Wnt signals (GO:0060070), leading to significantly blunted Wnt/β-catenin pathway activity in osteochondral cells (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This Wnt signal failure impairs limb bud development and growth plate function, particularly affecting the formation of the humerus and radius (www.ncbi.nlm.nih.gov). In summary, Omodysplasia’s core pathology is a developmental signaling failure* – Hedgehog pathway insufficiency (in OMOD1) and Wnt pathway perturbation (in OMOD2) – that converges on abnormal cartilage template formation and ossification. These molecular derangements translate into stunted bone growth, skeletal patterning defects, and the characteristic clinical dwarfism and dysmorphology.

Key Molecular Players

Genes/Proteins: The two genes causally implicated in Omodysplasia are GPC6 (HGNC:4454) and FZD2 (HGNC:4040). GPC6 encodes glypican-6, a glycosylphosphatidylinositol (GPI)-anchored heparan sulfate proteoglycan on the cell surface (pmc.ncbi.nlm.nih.gov). Glypican-6 acts as a co-receptor for morphogens; notably, it binds Hedgehog ligands and the Patched-1 (PTCH1) receptor to facilitate Hedgehog signal transduction in chondrocytes (pmc.ncbi.nlm.nih.gov). “GPC6 seems to have a previously unsuspected role in endochondral ossification and skeletal growth, and its functional abrogation results in a short-limb phenotype” (pmc.ncbi.nlm.nih.gov), as discovered by Campos-Xavier et al. (2009). All known disease-causing GPC6 mutations (e.g. nonsense and frameshift variants) produce truncated proteins lacking the GPI-anchor and heparan sulfate attachment sites, resulting in complete loss of glypican-6 function (pmc.ncbi.nlm.nih.gov). This abolishes GPC6’s ability to stimulate Hedgehog signaling, which is crucial for normal cartilage maturation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The FZD2 gene encodes Frizzled-2, a 7-transmembrane Wnt receptor. Frizzled-2 is broadly expressed during embryonic limb and craniofacial development (pmc.ncbi.nlm.nih.gov), where it transduces Wnt signals required for tissue patterning. Pathogenic FZD2 mutations in OMOD2 are typically truncating (e.g. a C-terminal nonsense mutation p.Trp548 identified by Saal et al., 2015 (pmc.ncbi.nlm.nih.gov)). The mutant Frizzled-2 protein is produced but lacks part of the cytoplasmic tail, including the conserved KTXXXW motif needed to recruit Dishevelled (DVL) upon Wnt binding (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). As a result, the truncated FZD2 cannot effectively initiate the canonical Wnt/β-catenin cascade. In functional assays, the truncated FZD2 was “significantly less efficient in transducing WNT signaling than the wild-type FZD2” (pmc.ncbi.nlm.nih.gov), leading to haploinsufficiency or a dominant-negative effect in Wnt-dependent developmental processes (pmc.ncbi.nlm.nih.gov). In addition to these primary genes, downstream signaling proteins are involved: for OMOD1, the Hedgehog pathway components such as the ligand Indian hedgehog (IHH) and its receptors PTCH1 and SMO (Smoothened) are relevant – GPC6 normally enhances their interaction (pmc.ncbi.nlm.nih.gov). For OMOD2, Wnt ligands (e.g. WNT5A and others expressed in limb mesenchyme) and intracellular effectors DVL2, β-catenin, and TCF/LEF* transcription factors play roles in the disrupted pathway (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Notably, WNT5A and its receptor ROR2 are linked to Robinow syndrome (a disorder with overlapping limb/facial phenotypes), highlighting that FZD2 mutations likely perturb similar developmental signaling routes (pmc.ncbi.nlm.nih.gov).

Chemical Entities: A key molecular entity in OMOD1 pathology is heparan sulfate (HS) – the glycosaminoglycan side chain of glypican-6. Heparan sulfate (CHEBI:28815) attached to GPC6 is essential for binding morphogens. GPC6’s HS chains physically interact with Hedgehog proteins and with PTCH1 (pmc.ncbi.nlm.nih.gov), effectively tethering the ligand-receptor complex. In GPC6 deficiency, this extracellular matrix factor is lacking, so Hedgehog ligands cannot form proper gradients or signaling complexes (pmc.ncbi.nlm.nih.gov). No specific exogenous small-molecule toxins or metabolites are known to cause Omodysplasia; it is a purely genetic disorder. However, the pathways involved have chemical modulators: for example, Wnt signaling inhibitors or Hedgehog pathway agonists are of theoretical interest. (To date, no drug therapy exists for Omodysplasia, but understanding that glypican-6 binds Hedgehog suggests that Hedgehog agonists might partially compensate, as observed in research models (pubmed.ncbi.nlm.nih.gov).) Overall, the relevant “chemical” players are the endogenous morphogen ligands (Hedgehog, Wnt) and the heparan sulfate matrix components facilitating their signaling.

Cell Types: The primary cell type affected in Omodysplasia is the chondrocyte (CL:0000138), specifically growth plate chondrocytes in developing long bones. GPC6 is normally expressed in proliferative zone chondrocytes of the growth plate (pmc.ncbi.nlm.nih.gov), which are the cartilage cells responsible for longitudinal bone growth. In GPC6-related OMOD1, these chondrocytes show markedly reduced signaling activity and impaired proliferation (pmc.ncbi.nlm.nih.gov). This leads to fewer chondrocytes maturing and hypertrophying, thus stunting bone elongation. Hypertrophic chondrocytes and osteoblasts (CL:0000062) are also indirectly affected, since Hedgehog signaling from prehypertrophic chondrocytes normally regulates their differentiation. In FZD2-related OMOD2, the affected cells include mesenchymal cells of the limb buds and osteochondral progenitors that rely on Wnt signals for proper patterning. Craniofacial osteoblasts and chondrocranial cells are similarly impacted by the disrupted Wnt signaling, explaining the facial dysmorphisms (www.ncbi.nlm.nih.gov). Notably, other cell types in organs that sometimes show anomalies (heart, genitalia) could be involved: for instance, cardiac valve mesenchyme and gonadal cells might be subtly affected due to the widespread roles of Wnt/Hedgehog in development (supporting the variable heart defects and cryptorchidism in some cases (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov)). Nonetheless, the disease pathology primarily centers on chondrocytes of the growth plate and their osteogenic counterparts.

Anatomical Locations: Omodysplasia chiefly involves the appendicular skeleton (UBERON:0002384), especially the proximal long bones of the arms and legs. The term “Omodysplasia” comes from Greek omos (shoulder), reflecting the prominent shortening of the humerus (UBERON:0002269) (pmc.ncbi.nlm.nih.gov). In autosomal dominant OMOD2, the upper limbs are most affected, with short humeri and elbow abnormalities (e.g., dislocated radial head of the radius bone (UBERON:0001306)) (www.ncbi.nlm.nih.gov). Autosomal recessive OMOD1 involves both upper and lower limbs: the humeri and femora (UBERON:0002445) are shortened and show metaphyseal flaring and distal tapering (narrowing towards the ends) (pmc.ncbi.nlm.nih.gov). The proximal radioulnar joint can be malformed (diastasis and radial head dislocation) leading to limited elbow extension (pubmed.ncbi.nlm.nih.gov). The knees may also be stiff due to abnormal distal femur and proximal tibia development (pmc.ncbi.nlm.nih.gov). The hands sometimes show shortened first metacarpals (UBERON:0001427), particularly in OMOD2 (www.ncbi.nlm.nih.gov). Craniofacial structures are another anatomical focus: patients have characteristic facial dysmorphology involving the skull and midface (UBERON:0001707) – including frontal bone prominence, nasal bridge, philtrum, etc. (see Phenotypes below). Additionally, some internal organs can be involved: for example, a subset of cases have congenital heart defects (e.g., atrial septal defect, patent ductus arteriosus) (pmc.ncbi.nlm.nih.gov), suggesting involvement of cardiac outflow tract structures (UBERON:0004174) during embryogenesis. Some males have cryptorchidism (undescended testes), implicating development of the inguinal canal/gubernaculum (UBERON:0036278). These systemic involvements are less consistent but highlight that the mutations affect developmental processes across multiple anatomical sites. Importantly, the epiphyseal growth plates (UBERON:0002495) of long bones are the central anatomical locations where the molecular pathology plays out, resulting in the limb deformities that define Omodysplasia (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Biological Processes (GO)

Several biological processes are disrupted in Omodysplasia, reflecting the roles of GPC6 and FZD2 in development:

  • Hedgehog signaling pathway (GO:0007224): The Hedgehog (Hh) signaling cascade is significantly downregulated in GPC6-related OMOD1. Normally, IHH produced by growth plate chondrocytes signals via PTCH1/SMO on neighboring cells to promote chondrocyte proliferation and prevent premature hypertrophy. Glypican-6 is required to efficiently present Hedgehog ligand to its receptor at the cell surface (pmc.ncbi.nlm.nih.gov). In GPC6-deficient chondrocytes, Hedgehog pathway activity is “significantly reduced in the long bones” (pmc.ncbi.nlm.nih.gov), leading to a failure of proper growth plate signaling. This is evidenced by GPC6-null mouse embryos, which show curtailed Hh signaling and recapitulate the Omodysplasia skeletal phenotype (pmc.ncbi.nlm.nih.gov). Thus, the normal biological process of Hedgehog-mediated signal transduction in bone development is impaired, causing truncated bone growth.

  • Wnt signaling pathway (canonical) (GO:0060070): Wnt/β-catenin signaling is perturbed in FZD2-related OMOD2. Canonical Wnt signaling in osteoblast and chondrocyte precursors drives cell proliferation and skeletal patterning during limb and craniofacial development. The Frizzled-2 receptor normally binds Wnt ligands and, via Dishevelled, stabilizes β-catenin for gene transcription. In OMOD2, the mutated Frizzled-2 cannot propagate the Wnt signal, leading to markedly diminished pathway output (pmc.ncbi.nlm.nih.gov). Saal et al. (2015) showed that cells expressing the mutant FZD2 failed to activate a Wnt-responsive luciferase reporter (TOPFLASH assay), whereas wild-type FZD2 yielded ~3-fold induction (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The authors conclude the patients’ cells are effectively haploinsufficient for Wnt signaling during skeletal development (pmc.ncbi.nlm.nih.gov). Therefore, the biological process of canonical Wnt signal transduction is disrupted in Omodysplasia, contributing to abnormal limb formation and bone growth.

  • Endochondral ossification (GO:0001958): This is the process by which cartilage is gradually replaced by bone in the developing skeleton. Endochondral ossification is fundamentally impaired in Omodysplasia (pmc.ncbi.nlm.nih.gov). Due to Hedgehog and Wnt signaling defects, the coordination between chondrocyte maturation and osteoblast activity is lost. Normally, proliferating chondrocytes lay down a cartilage template, then undergo hypertrophy and apoptosis, while osteoprogenitors invade to form bone tissue. In GPC6-deficient individuals, endochondral bone formation is delayed and disorganized (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Growth plates show reduced chondrocyte proliferation and possibly altered hypertrophic zones, leading to shortened metaphyses. Campos-Xavier et al. noted that loss of GPC6 abrogates a critical function in endochondral ossification, resulting in the short-limb dwarfism phenotype (pmc.ncbi.nlm.nih.gov). Thus, the entire sequence of events in endochondral bone growth is disrupted – a central pathophysiological mechanism in Omodysplasia.

  • Cartilage development and morphogenesis (GO:0051216, GO:0060350): Related to ossification, the early developmental processes of cartilage patterning in the limb are also affected. GPC6 and FZD2 mutations alter the behavior of limb bud mesenchymal cells that condense into cartilage models of bones. Aberrant Hedgehog/Wnt signaling likely disturbs chondrocyte differentiation (GO:0035988) and cartilage morphogenesis. For example, the organization of growth plate cartilage is abnormal in GPC6-null mice, who display shortened long bone cartilage templates and delayed ossification centers (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Similarly, FZD2-related Wnt deficits can affect cell fate specification in limb mesenchyme (a Wnt-driven process), leading to defects like missing or shortened bone segments (e.g. first metacarpal shortening in OMOD2 (www.ncbi.nlm.nih.gov)). Although specific gene ontology terms cover these sub-processes, collectively Omodysplasia disrupts normal skeletal system development (GO:0001501) and cartilage/bone maturation at multiple stages.

  • Morphogen gradient formation: Though not a formal GO term, it’s worth noting that Omodysplasia illustrates problems in morphogen distribution. Glypican-6 normally helps establish proper gradients of Hedgehog in the growth plate microenvironment (pmc.ncbi.nlm.nih.gov). In its absence, the spatial-temporal pattern of IHH signaling is likely altered. Indeed, heparan sulfate proteoglycans (like GPC6) “play a role in regulating essential developmental events, such as morphogen gradient formation” (pmc.ncbi.nlm.nih.gov). This general process underlies how signaling pathways orchestrate tissue patterning, and its disturbance is a theme in the disease.

Overall, Omodysplasia affects critical developmental biological processes: signaling pathways (Hh, Wnt), cartilage anlage formation, and ossification. This multi-level disruption in skeletogenesis explains the clinical features of the disease.

Cellular Components

The molecular pathology of Omodysplasia unfolds at specific cellular locations and structures:

  • Plasma membrane (GO:0005886): Both glypican-6 and Frizzled-2 function at the cell surface. Glypican-6 is anchored to the external leaflet of the plasma membrane via a GPI anchor (pmc.ncbi.nlm.nih.gov), positioning its heparan sulfate chains to interact with extracellular ligands. Frizzled-2 is a transmembrane receptor spanning the plasma membrane, with an extracellular domain binding Wnt and an intracellular tail transmitting signals. The disease-causing FZD2 mutation truncates the intracellular tail, so the mutant receptor still localizes to the membrane and can bind Wnt ligand but cannot relay the signal inward (pmc.ncbi.nlm.nih.gov). Thus, the cell membrane is a key site: in OMOD1, the membrane is deficient in GPC6 co-receptors; in OMOD2, it bears non-functional FZD2 receptors. These defects at the plasma membrane compromise the initiation of Hedgehog and Wnt signaling cascades.

  • Primary cilium (GO:0031513): The primary cilium is a microtubule-based organelle on the surface of chondrocytes that acts as a hub for Hedgehog signal transduction. Patched-1 (PTCH1) and Smoothened localize to cilia to transduce Hedgehog signals once IHH is present. Recent research showed that glypican-6 shuttles to the cilium upon Hedgehog stimulation: “in the absence of Hh, GPC6 is localized outside of the cilium but moves into the cilium upon addition of Hh” (pmc.ncbi.nlm.nih.gov). GPC6 appears to facilitate the interaction of Hedgehog ligand with PTCH1 at the ciliary membrane (pmc.ncbi.nlm.nih.gov). In GPC6-null cells, Hedgehog cannot effectively activate signaling in the cilium, as evidenced by loss of downstream Gli activation (pmc.ncbi.nlm.nih.gov). Therefore, the primary cilium of growth plate chondrocytes is a critical cellular component impacted by Omodysplasia – without GPC6, the Hedgehog reception in cilia is blunted. (Notably, ciliary dysfunction is not primary here, but the lack of a co-receptor in cilia has a similar outcome: reduced Hh pathway output.)

  • Extracellular matrix (GO:0031012): The cartilage extracellular matrix (ECM) is the milieu where signaling molecules diffuse and act. Glypican-6, via its heparan sulfate chains, is a component of the pericellular matrix that sequesters and presents growth factors. In OMOD1, the ECM in the growth plate lacks functional GPC6, likely altering the distribution of IHH and possibly other growth factors (FGFs, BMPs) that bind HSPGs (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The absence of GPC6 in the matrix may lead to rapid diffusion or uneven gradients of Hedgehog, failing to properly maintain the proliferative vs. hypertrophic zones of cartilage. Additionally, the ECM component chondroitin sulfate can also influence growth plate signaling, but it’s the deficit of the heparan sulfate proteoglycan that is central in this disease. In summary, the ECM immediately around chondrocytes is a key compartment – Omodysplasia perturbs the normal ECM-morphogen interactions necessary for organized ossification.

  • Cytoskeleton/Dishevelled puncta: In OMOD2, an interesting cellular phenotype is observed in the cytoplasm regarding Dishevelled (DVL) localization. In unstimulated cells, DVL is found in cytosolic punctate complexes. When Wnt binds to a Frizzled receptor, DVL relocates to the plasma membrane to propagate the signal. In cells expressing mutant FZD2, recruitment of DVL to the membrane upon Wnt stimulation is greatly reduced (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Microscopy showed that with Wnt, wild-type FZD2 co-localizes with DVL at the membrane, whereas FZD2^Trp548* fails to recruit DVL, leaving DVL in cytosolic puncta (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This suggests that the cytosolic signalosome assembly (a complex of FZD–DVL–Axin, etc.) at the inner leaflet of the membrane is defective. So while not a specific organelle, the subcellular localization of signal proteins (membrane vs cytosol) is an important cellular component aspect – Omodysplasia involves failure to form the membrane-associated Wnt signalosome due to the truncated FZD2.

In summary, Omodysplasia’s molecular defects manifest at the cell surface (membrane receptors/co-receptors), within specialized surface organelles (primary cilium for Hh signaling), and in the extracellular space (matrix ligand distribution). These disrupted cellular component locales underlie the breakdown of intercellular communication required for normal skeletal morphogenesis.

Disease Progression

Omodysplasia is a developmental disorder present from birth, so its “progression” is best understood as a series of events during growth rather than a degenerative timeline. The initiating event is the inheritance (or de novo occurrence) of a pathogenic mutation in GPC6 or FZD2 at conception. This genetic defect sets off an abnormal developmental program in the embryo. During early embryogenesis, limb bud formation and skeletal patterning are altered due to impaired signaling. For instance, in FZD2-related cases, the limb buds may already exhibit abnormal proximal-distal patterning, contributing to humeral shortening. As endochondral ossification commences in the fetus, the effects become pronounced: by mid-gestation (~20 weeks), prenatal ultrasound can detect markedly shortened long bones (rhizomelia) in severe cases (pmc.ncbi.nlm.nih.gov). Bayat et al. (2020) reported a family where a routine 21-week scan showed severe shortening of all limbs in an affected fetus (pmc.ncbi.nlm.nih.gov). Thus, the disease process is active in utero, with insufficient growth plate expansion and bone formation from the second trimester onward.

At birth, the clinical phenotype is fully manifest: infants present with disproportionate short stature (short limbs with relatively normal trunk) and characteristic facial features. Birth length is often far below the typical range (one reported OMOD1 neonate was 45 cm at term, <<1st percentile (pmc.ncbi.nlm.nih.gov)). Despite the skeletal abnormalities, newborns are usually medically stable (weight can be near normal, and vital organ function is generally intact aside from occasional heart defects). Postnatally, the disease does not “progress” in the sense of new systems failing, but the consequences of the developmental anomalies persist. During childhood, the growth velocity of long bones remains low because the fundamental signaling deficits continue to limit chondrocyte function. This leads to short stature becoming more pronounced over time (final adult heights in recessive Omodysplasia range ~132–144 cm, about −5 to −7 SD below mean height) (pmc.ncbi.nlm.nih.gov). The limb deformities (e.g. elbow dislocations, bowed radii) may become more functionally significant as the child grows and tries to use their limbs, sometimes requiring orthopedic interventions.

Omodysplasia does not typically have distinct clinical stages; it is relatively static after the growth period is complete. One might consider the infancy/childhood phase (when growth plates are open) as the period where the skeletal differences emerge and increase relative to peers, followed by an adult phase where stature is fixed and secondary complications may appear. For instance, limited joint mobility in elbows and knees can lead to muscle contractures if not managed with physiotherapy. There is no evidence of progressive degeneration in bones – the bones are abnormal in shape/size but not known to deteriorate or fracture pathologically (unless secondary osteoporosis occurs in older age, which hasn’t been reported specifically for Omodysplasia). Intellectual development is usually normal, though a few cases of developmental delay are noted in the recessive form (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov) – this may be related to other congenital issues or mild structural brain differences, but data are sparse. Life expectancy is not well-documented due to the rarity, but patients have been reported into adulthood (pmc.ncbi.nlm.nih.gov). In summary, the “progression” is chiefly the unfolding of developmental abnormalities: from a genetic lesion to aberrant embryonic skeletal patterning, to detectable fetal bone shortening, to neonatal dwarfism, and finally to short-statured adulthood with possible orthopedic challenges. There are no phases of remission or relapse – the condition is continuously present from womb to adult life, defined by the consequences of early developmental disruptions.

Phenotypic Manifestations

Omodysplasia’s clinical phenotype centers on the skeleton, with secondary effects in other systems. Key manifestations and their mechanistic underpinnings include:

  • Disproportionate Short Stature (Rhizomelic dwarfism): Almost all patients have significantly short stature primarily due to shortened proximal long bones (rhizomelia). This phenotype directly reflects impaired endochondral ossification in the humeri and femora. The arms and thighs are much shorter than normal, while the head and trunk are relatively normal in size. In recessive OMOD1, both upper and lower limbs are severely affected, leading to very short overall height (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In dominant OMOD2, the short stature may be mild or borderline (some patients have near-normal height), with a more pronounced effect in the arms (pubmed.ncbi.nlm.nih.gov). For example, an OMOD2 case had normal stature but clearly shortened humeri and restricted elbow movement (pubmed.ncbi.nlm.nih.gov). The rhizomelic shortening is a direct consequence of reduced chondrocyte proliferation in the growth plate – fewer and thinner growth plate columns yield shorter bones.

  • Limb Abnormalities and Joint Limitations: Beyond length, the shape of bones and joints is altered. Distal tapering of long bones (club-like flaring of the metaphyses) is often noted on X-rays (pmc.ncbi.nlm.nih.gov). The elbows are characteristically abnormal: many patients have proximal radioulnar diastasis with radial head dislocation (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This leads to limited extension and rotation at the elbow. The mechanism is that improper signaling during elbow joint formation (which involves segmented growth of radius/ulna) leads to malformed joint surfaces. Cubitus varus (inward angulation of elbow) may be seen. The knees can also be stiff with limited range, partly due to shortened distal femur and fibular bowing. In some cases, contractures or pterygia (webbing) at the knees and elbows were reported (pmc.ncbi.nlm.nih.gov), likely secondary to reduced motion in utero. Hands and feet: OMOD2 often shows a short first metacarpal, causing a form of brachydactyly (the thumb appears proximally placed) (www.ncbi.nlm.nih.gov). OMOD1 hands can be relatively normal or mildly shortened. Overall, limb joint limitations reflect the underlying structural abnormalities in bone geometry caused by dysregulated growth plate development.

  • Craniofacial Dysmorphism: Characteristic facial features are present, especially in OMOD1. These include frontal bossing (prominent forehead), a somewhat bulbous broad face, depressed nasal bridge with a short nose and anteverted (upturned) nostrils, and a long prominent philtrum (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Hypertelorism (wide-spaced eyes) and relative macrocephaly (large-appearing head due to short stature) are sometimes noted (pubmed.ncbi.nlm.nih.gov). Newborns can have a frontal capillary hemangioma (stork bite or nevus flammeus on the forehead) in some cases (pmc.ncbi.nlm.nih.gov), although this is a minor finding. The craniofacial anomalies have parallels to Robinow syndrome (another short-limb condition involving Wnt5A/ROR2), underlining the Wnt-signaling disturbance in OMOD2 (pubmed.ncbi.nlm.nih.gov). Mechanistically, insufficient Wnt signaling via FZD2 in craniofacial mesenchyme likely leads to midface hypoplasia and the nasal bridge defect. Likewise, Hedgehog signaling (particularly Sonic hedgehog) is critical in facial patterning; glypican-6 loss might subtly affect SHH gradients in the developing face, contributing to these dysmorphic features (pmc.ncbi.nlm.nih.gov). Notably, in OMOD2 (FZD2 mutations), the craniofacial phenotype can closely resemble mild autosomal dominant Robinow syndrome (frontal bossing, nasal bridge depression, etc.) (pubmed.ncbi.nlm.nih.gov), consistent with disruption of Wnt/planar cell polarity pathways.

  • Chest and Spine: The axial skeleton is generally less affected. Spine length is relatively preserved (no significant dwarfism of the spine), and there are no consistent vertebral anomalies reported in Omodysplasia. Scoliosis is not a known feature. The chest may appear normal; however, some patients have been noted to have pectus carinatum or excavatum in other short-limb syndromes, but this isn’t emphasized in OMOD literature. Radiologically, no major vertebral segmentation defects or rib abnormalities have been described (pmc.ncbi.nlm.nih.gov). This contrasts with some other skeletal dysplasias, highlighting that Omodysplasia’s effects are mostly appendicular and craniofacial.

  • Genitourinary Anomalies: A subset of patients, especially males with recessive OMOD1, exhibit cryptorchidism (undescended testicles) (pmc.ncbi.nlm.nih.gov). This was present in the first reported families and is considered part of the phenotype variability (pmc.ncbi.nlm.nih.gov). Cryptorchidism could result from impaired androgen-driven gubernaculum development or abdominal pressure issues; however, since it’s not in all cases, it might reflect Wnt pathway roles in gonadal descent (Wnt5a is known to influence reproductive tract development). Some patients also have kidney or urinary tract anomalies reported anecdotally, but data is scarce. In OMOD2, hypoplastic genitalia or anomalies were mentioned as “variable genitourinary anomalies” in the original description (www.ncbi.nlm.nih.gov), though not in every case. For example, one male patient had cryptorchidism, while another had normal genital development (www.ncbi.nlm.nih.gov). These features indicate that while not the core of the disease, developmental pathways affected by GPC6/FZD2 can extend to the genitourinary system.

  • Cardiac and Other Organ Systems: There have been few reports of congenital heart defects in Omodysplasia (pmc.ncbi.nlm.nih.gov). Specifically, conditions like coarctation of the aorta, atrial septal defect (ASD), patent ductus arteriosus (PDA), or valve anomalies were noted in some cases of OMOD1 (pmc.ncbi.nlm.nih.gov). In the 2009 series, 2 of 8 patients had heart defects (pmc.ncbi.nlm.nih.gov). While not every patient is affected, these occurrences suggest that the genetic defect might subtly impact cardiac morphogenesis (possibly through impaired signaling in cardiac neural crest or endocardial cushion cells, where Hh/Wnt also play roles). No consistent gastrointestinal or pulmonary abnormalities have been tied to Omodysplasia.

  • Neurological and Cognitive: Omodysplasia is primarily a bone disorder, and most patients have normal intelligence and no major neurological deficits. However, variable developmental delay and mild intellectual disability were reported in a few of the early recessive cases (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). For instance, Campos-Xavier et al. mentioned “variable developmental delay” among their cases (pmc.ncbi.nlm.nih.gov). It’s unclear if this is due to the genetic defect’s effect on brain development or secondary to other issues (like chronic medical concerns or less optimal social development). Glypicans are expressed in the central nervous system and involved in neurodevelopmental signaling gradients (pmc.ncbi.nlm.nih.gov), so in theory a GPC6 mutation might have minor CNS effects. A recent case report (Das et al., 2024) even described an adult with Omodysplasia and treatment-resistant schizophrenia (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), speculating on a link between the Wnt/Hedgehog pathway genes and neurodevelopment. However, this appears to be an isolated case; no definitive neurobehavioral phenotype is established for Omodysplasia (pmc.ncbi.nlm.nih.gov). Occasionally noted are hypotonia and motor delay in infancy (likely due to the orthopedic limitations). Seizures or major CNS malformations are not typical. In summary, most individuals with Omodysplasia do not have significant cognitive impairment, though a few have had mild delays, and rare psychiatric comorbidity has been observed anecdotally.

In conclusion, the phenotype of Omodysplasia spans primarily skeletal abnormalities – short limbs, joint dysplasia, facial dysmorphism – with occasional extraskeletal features like heart defects or cryptorchidism. These clinical manifestations align with the underlying molecular mechanisms: disrupted Hedgehog and Wnt signaling during development leads to errors in bone growth and patterning, which manifest as the unique constellation of Omodysplasia features. Each phenotypic trait, from rhizomelic short stature to craniofacial features, can be traced back to the developmental pathways derailed by GPC6 or FZD2 mutations. The rarity of the condition (fewer than 30 reported AR cases by 2009 (pmc.ncbi.nlm.nih.gov) and only ~10 AD cases by 2022 (pubmed.ncbi.nlm.nih.gov)) underscores that our understanding of the full phenotype spectrum is still evolving. Recent studies, such as a 2023 report of five siblings with a mild missense GPC6 variant, have expanded the known phenotype to include milder rhizomelia with partial function retained (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). Those findings support the correlation between the molecular severity and clinical severity: even a hypomorphic GPC6 mutation that somewhat reduces Hedgehog signaling can cause short stature, albeit less extreme (pubmed.ncbi.nlm.nih.gov). Thus, Omodysplasia provides a clear example of how perturbation of key signaling pathways in the embryo leads to predictable abnormalities in anatomy and growth, and ongoing research and case reports continue to refine the genotype–phenotype correlations in this rare skeletal dysplasia.

Evidence: The pathophysiological insights above are supported by numerous studies. Campos-Xavier et al., 2009 (American Journal of Human Genetics) first identified GPC6 mutations as the cause of recessive Omodysplasia and documented the loss of function in endochondral ossification (pmc.ncbi.nlm.nih.gov). Saal et al., 2015 (Human Molecular Genetics) discovered the FZD2 mutation in dominant Omodysplasia and demonstrated its impact on Wnt signaling using cell-based assays (pmc.ncbi.nlm.nih.gov). Capurro et al., 2017 (J Cell Biol) provided mechanistic evidence in Gpc6-knockout mice that glypican-6 enhances Hedgehog signaling at the primary cilium (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). A 2020 case report by Bayat et al. described novel GPC6 variants and prenatal presentation (pmc.ncbi.nlm.nih.gov). Most recently, Crenshaw et al., 2023 (Am J Med Genet) reported a milder phenotype with a partial-function GPC6 mutation, confirmed via Hedgehog activity assays (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). These and other references furnish a consistent picture of Omodysplasia’s molecular basis and clinical manifestations, solidifying our current understanding of this rare skeletal disorder.